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ABSTRACT
Lung cancers are a leading cause of death worldwide, and although there is some
evidence that both Epidermal Growth Factor Receptor (EGFR) and Wnt/-catenin
signalling are involved in initiation and progression of this disease the molecular
mechanisms regulating these processes remain poorly described. Here I show that deletion
of LRIG1, an endogenous EGFR inhibitor, leads to epithelial hyperplasia in the murine
airway and continued proliferation post confluence in vitro. This occurs via
phosphorylation of EGFR and its downstream effector molecule ERK1/2. Human lung
cancer cell lines lacking LRIG1 showed a reduction of proliferation on LRIG1
replacement. Using co-localisation experiments I have defined LRIG1 inhibition of
density dependent growth occurs through LRIG1 forming a complex with EGFR and
E-Cadherin at the cell confluence. Examination of matched human pre-invasive lung
cancer lesions with normal airway from the same individuals delineated loss of LRIG1
supporting its role in the early stages of cancer development.
I further show that -catenin regulates epithelial cell phenotype in both normal airway
stem cells and preinvasive lung cancers. -catenin inhibition within keratin 14-expressing
stem cells impairs airway repair whilst activation increases cell proliferation, directs
lineage choice, and promotes an epithelial-to-mesenchymal transition that includes loss of
cadherin-mediated adhesions and increased Twist and Snail transcription influencing both4
intercellular and cell-matrix adhesiveness. These findings were recapitulated in vitro both
by pharmacological -catenin activation and direct E-cadherin inhibition. Thus,
-catenin modulation of cadherin-dependent intercellular adhesions determines cell
phenotype and its overexpression is a key early step in pre-invasive disease development.5
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CHAPTER 1. INTRODUCTION
1.1 Background
Lung cancer is the world’s most common fatal cancer, with non small cell lung cancer
(NSCLC) accounting for 80% of all cases (Felip, Cedres et al.). Given the fact that
cigarette smoking causes 90% of lung cancers worldwide (Giangreco, Groot et al. 2007),
one hypothesis is that this disease is caused by the failure of restoration of normal
homeostatic cell division after injury. Therefore, understanding the mechanism involved
in normal airway epithelial maintenance and repair after injury is crucial for lung cancer
early detection and possibly therapy.
1.2 Airway homeostasis and repair
1.2.1 Normal airway cellular composition in mouse and human upper
airway
In mice, the airway epithelium is pseudostratified in the large airways, becoming
columnar in the intrapulmonary airways and cuboidal in the small airways. The trachea isChapter 1. Introduction
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lined by a pseudostratified epithelium comprising about 30% basal cells, 55% ciliated
cells, a few secretory cells and sparse neuroendocrine cells (Rock, Randell et al.). The
intrapulmonary airways (bronchioles) are lined by a columnar epithelium consisting of
Clara and ciliated cells with interspersed clusters of neuroendocrine (NE) cells (Rawlins,
Okubo et al. 2009). The more distal airways have fewer ciliated cells compared to more
proximal airways, whilst basal cells are absent in intrapulmonary airways and further
distally (Rock, Randell et al. 2010). The major populations of cells within the upper
airways can be immunophenotyped by the expression of Keratin 14/ Keratin 5 (K14/K5)
in basal cells, Clara cells expressing high levels of secretoglobin SCGB1A1, also known
as CCSP, and ciliated cells expressing acetylated tubulin (Mercer, Russell et al. 1994).
In humans, the airway epithelium remains pseudostratified from trachea to terminal
bronchioles before it turns into a simple cuboidal epithelium lacking basal cells in the
respiratory bronchioles. The pseudostratified epithelium has a higher number of secretory
cells than in mice and consists of ~ 30% basal cells, 30% ciliated cells and 30% secretory
cells (majorly goblet cells and a few Clara cells) (Mercer, Russell et al. 1994). Hence, the
mouse tracheal epithelium is similar to the upper human airways and is the model system
I use in large parts of my thesis.Chapter 1. Introduction
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Figure 1.1 Diagram showing the cellular composition of the mouse trachea
The pseudostratified epithelium in mouse tracheal comprises basal, ciliated and Clara cells in
similar proportions. The submucosal glands (SMGs) are only present in the proximal trachea. In
laboratory mice, goblet cells which responsible for mucus producing are largely restricted to the
SMGs. (Adapted from Rock et al. 2010)
1.2.2 Epithelial homeostasis and repair
1.2.2.1 Airway epithelial homeostasis
Maintenance of respiratory epithelium in steady state involves the balance between
airway epithelial cell proliferation, differentiation and apoptosis. Disruption of this
balance and failure to restore homeostasis may lead to the pathological changes such as
hyperplasia, metaplasia or carcinogenesis. Hence, a greater understanding and control of
the involved signalling pathways is clinical relevant.Chapter 1. Introduction
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The airway epithelium is slowly renewing compared with the tissues such as the intestine
or skin. Turnover of the intestinal epithelium occurs in around 5 days (Snyder, Teisanu et
al. 2009) compared to the estimated half-life of ciliated cell lifespan of 6 months in
trachea and 17 months in the bronchi (Rawlins and Hogan 2008).
Many tissues such as pancreas, skin, and corneal epithelium, are maintained by the
non-stem progeny, named transit amplifying cells, undergo a small number of rounds of
division before withdrawing from the cell cycle and undergoing terminal differentiation
(Dor, Brown et al. 2004; Dor and Melton 2004; Teta, Rankin et al. 2007; Majo, Rochat et
al. 2008). Interestingly chimeric studies in the lower airways have demonstrated a
stochastic self-renewal of Clara cells is responsible for intrapulmonary airway
homeostasis (Giangreco, Arwert et al. 2009).
In the steady state tracheal epithelium, basal cells have been shown to, over a long period
of time, self-renew and give rise to both Clara cells and ciliated cells (Rawlins, Okubo et
al. 2009).
1.2.2.2 Airway epithelial repair
A variety of animal models have been developed to investigate the repair process.
Methods to induce proximal airway injury are: intratracheal instillation of detergent
polidocanol, which causes widespread removal of epithelium; SO2 inhalation, which
destroys the luminal cells non-selectively; and naphthalene intraperitoneal injection,
which cause selective death of Clara cells due to the enrichment of cytochrome P450
where the naphthalene is metabolised into toxic derivatives (Borthwick, Shahbazian et al.Chapter 1. Introduction
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2001; Hong, Reynolds et al. 2004). These models induce variable damage but a similar
early epithelial repair process. After the neighboring cells migrate and spread to cover the
denuded surfaces, cells undergo proliferation. When new-formed epithelial cells reach
confluence, they undergo contact inhibition and begin to differentiate and restore normal
epithelium (Borthwick, Shahbazian et al. 2001; Burgel and Nadel 2004).
In the trachea, only basal cells and a few Clara cells survive after the non-selective injury.
Lineage labelling of basal cells has shown that surviving basal cells throughout the
trachea divided and gave rise to ciliated and Clara cells (Rock, Onaitis et al. 2009).
K14-expressing basal cells were also demonstrated to self-renew after specific Clara cell
ablation, and generate Clara and ciliated cells after injury (Hong, Reynolds et al. 2004).
1.3 The EGFR pathway’s role in airway epithelial homeostasis
and repair
1.3.1 EGFR family signalling
The epidermal growth factor receptor (EGFR) was identified in 1978 by Cohen and
co-workers as a 170-kDa membrane component, which was expressed in cells of
mesodermal and ectodermal origins (Yarden and Sliwkowski 2001). EGFR consists of
three functional domains, one extracellular region providing the ligand-binding site and
dimerisation arm, a transmembrane domain, and a highly-conserved cytoplasmic region
that encodes a tyrosine kinase and multiple phosphorylation residues. The EGFR familyChapter 1. Introduction
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comprises four structurally related receptor tyrosine kinases (RTK), which are
EGFR/ErbB-1/HER-1 (Human Epidermal growth factor Receptor), ErbB-2/Neu/HER-2,
ErbB-3/HER-3, and ErbB-4/HER-4. These receptors can be activated by a number of
growth factors (Linggi and Carpenter 2006) and regulate diverse functions in normal cells
and have a crucial role in tumorigenesis. There are three functional groups of epidermal
growth factor family. The first group only binds to EGFR, consisting of EGF and its
analogues TGF- (transforming growth factor alpha), amphiregulin (AR, also known as
keratinocyte autocrine factor or colorectum-cell derived growth factor). The second group
binds to ErbB3 and ErbB4, consisting of Neuregulins, also known as heregulins. The third
group binds both EGFR and ErbB4, consisting of batacellulin, epiregulin, and HB-EGF
(heparin-binding epidermal growth factor-like factor) (Riese and Stern 1998).
Ligand binding leads to the dimerisation of receptors, and the resulting conformational
change has been proposed as an essential step for kinase activation, apart from certain
constitutively active mutants (Linggi and Carpenter 2006). Receptor dimerisation,
including both homo- and heterodimerisation, results in the autophosphorylation of
multiple tyrosine residues within the cytoplasmic domain. The activated EGFR recruits a
number of signal transducers to their docking site within the cytoplasmic domain, such as
growth-factor-receptor bound-2 (GRB2) and Src-homology-2-containing (Shc). GRB2
and Shc can recruit Ras and subsequently activate the mitogen-activated protein kinase
(MAPK or Erk2) pathway, as well as the Ras/PI3K/AKT/PKB pathway (Citri and Yarden
2006).Chapter 1. Introduction
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1.3.2 Downstream Ras/MAPK/ERK signalling
MAPK cascade comprises a MAPK kinase kinase (MAP3K), a MAPK kinase (MAP2K)
and a MAPK. The terminal MAPKs are the ERK, JNK (also called SAPK), p38 and
ERK5 kinases (Montagut and Settleman 2009). Upon RAS activation, RAF kinase is
subsequently phosphorylated leading to stimulation of its serine-threonine kinase activity
(Malumbres and Barbacid 2003), which results in sequential phosphorylation and
activation of the MEK1/MEK2 protein kinases and ERK. Activated ERKs translocates to
the nucleus where they induce the transcription of immediate early genes, such as Elk1,
Fos, Jun and Myc, which encode transcription factor and change the expression level of
other genes responsible for cell proliferation (Yoon and Seger 2006).
1.3.3 Downstream Ras/PI3K/AKT/PKB signaling
EGFR activation by multiple ligands leads to the recruitment and subsequent stimulation
of class I PI3K. PI3K can also be activated by RAS. The activated kinase catalyses the
phosphorylation of phosphatidylinositol bisphosphate (PIP2) to phosphatidylinositol
triphosphate (PIP3), the latter one acts as a docking site for Akt. Akt is a serine-threonine
kinase which performs as the key regulator of the PI3K pathway, and
phosphoinositide-dependent kinase 1. Upon the phosphorylation, Akt is activated and
exerts its effects in the cell by phosphorylating various downstream substrates such as
BAD (BCL2 Antagonist of Cell Death), Caspase 9, FKHR (Forkhead TranscriptionalChapter 1. Introduction
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Factor) and therefore regulates apoptosis, cell growth and mobility (Baselga, 2009).
Figure 1.2 overview of EGFR signalling pathway.
Abbreviations: PIP2, phosphatidylinositol bisphosphate; PIP3, phosphatidylinositol triphosphate,
PDK1, 3-phosphoinositide-dependent protein kinase 1; PI3K, hosphoinositide-3 kinase; GRB2,
growth-factor-receptor bound-2; SOS, son of sevenless; MEK: mitogen-activated protein kinase;
RAS, a protein subfamily of small GTPases; RAF, MAPK kinase kinase (MAP3K); ERK,
extracellular signal-regulated kinase.Chapter 1. Introduction
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1.3.4 Nuclear EGFR signalling
In addition to the canonical signalling pathway occurring at the plasma membrane
described above, there appears to be nuclear EGFR signalling. Intact EGFR, likely in the
phosphorylated form, has been detected in the nucleus. Experiments have demonstrated
this occurs in both ligand-dependent and ligand-independent manner (Lin, Makino et al.
2001; Cordero, Cozzolino et al. 2002; Dittmann, Mayer et al. 2005). The initial step of
receptor trafficking likely depends on its internalisation. It has been proposed that EGFR,
without a putative DNA binding site, first associates with DNA-binding transcription
factor STAT3, and then targets promoters such as cyclin D1 and B-myb. By upregulating
the promoter expression, EGFR therefore positively regulates G1/S cell cycle progression
which is closely associated with tumorigenesis, tumor proliferation and progression (Lo,
Hsu et al. 2005; Hanada, Lo et al. 2006). However, to what extent in vivo nuclear EGFR
effects cell homeostasis remains largely unknown and requires further investigation.
1.3.5 EGFR regulation
1.3.5.1 Endocytosis and degradation of EGFR
On ligand-binding and subsequent dimerisation, receptors undergo internalisation into
endosomes where the ligand-receptor complex either experiences disassociation followed
by recycling back to the cell surface in a kinase-independent manner, or recruits c-Cbl, anChapter 1. Introduction
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E3 ubiquitin ligase, and undergoes ubiquitylation. Notably, the other three ErbB proteins
are more often recycled back to the cell surface due to the impaired endocytosis. C-Cbl
preferentially binds to the EGFR homodimers either directly (Tyr 1045) or indirectly
through GRB2 (Waterman, Katz et al. 2002),
1.3.5.2 Intrinsic EGFR regulators
1.3.5.2.1 MIG6
Mitogen-inducible gene-6 (MIG6), also known as receptor-associated late transducer
(RALT), Errfi1 (ErbB receptor feedback inhibitor 1) or gene 33, was the first feedback
inhibitor discovered in mammalian cells. It is a 50-kDa adapter Protein and able to bind to
the kinase domain of EGFR family, and directly inhibit the EGFR catalytic activity (Xu,
Makkinje et al. 2005; Anastasi, Baietti et al. 2007). Overexpression of MIG6 in cultured
cells contributed to the suppression of EGFR activation and downstream signalling (Xu,
Makkinje et al. 2005). Loss of MIG6 resulted in increased tyrosine phosphorylation of
EGFR in primary keratinocytes isolated from MIG6-defective mice. These mice also
experienced overproliferation and impaired differentiation of epidermal keratinocytes,
eventually developed spontaneous tumors in various organs (Ferby, Reschke et al. 2006).
1.3.5.2.2 LRIG1
The LRIG1 (leucine-rich and immunoglobulin-like domain 1) protein is an integral
membrane protein, comprising an extracellular part consisting of a leucine-rich repeat
(LRR) domain and three immunoglobulin-like domains, a transmembrane region and aChapter 1. Introduction
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cytoplasmic tail. The LRIG family comprises three structurally similar proteins, LRIG1-3,
which also share molecular functions (Hedman and Henriksson 2007).
Figure 1.3 Schematic drawing of the LRIG1 construct.
LRIG1 comprises an extracellular domain including the leucine-rich repeat domain (LRR) and
immunoglobulin-like domain (Ig), a transmembrane domain (TM) and a cytoplasmic domain. Either
the extracellular or the Ig-like domains are sufficient to couple with EGFR
LRIG1 is considered a negative regulator of EGFR signalling. In vitro work on various
human cell lines shows that LRIG1 expression is induced upon receptor activation,
followed by binding to the extracellular domain of EGFR whilst its juxtamembrane
domain constitutively recruits and activates c-Cbl, therefore facilitating EGFR
unbiquitylation. In the mutant Y1045F-EGFR, whose cbl-docking site was mutated and
underwent only minimal cbl-dependent unbiquitylation, LRIG1 supplied a surrogateChapter 1. Introduction
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mechanism that enables cbl recruitment and subsequent receptor degradation (Gur, Rubin
et al. 2004). However, another in vitro study using a different ectodomain of LRIG1
fragment, consisting of only the extracellular domain, could also suppress EGFR
signalling and cell proliferation (Goldoni, Iozzo et al. 2007). Consistent with this result,
Yi et al. reported that ectopic LRIG1 could be cleaved by ADAM (a metalloproteinase)
and released extracellular domain which inhibited EGFR signalling without the
downregulation of receptor expression. Therefore the author proposed a novel paracrine
mechanism by which LRIG1 inhibits the EGFR signalling by competing with EGF for
binding to EGFR (Yi, Holmlund et al. 2011).
The interaction of LRIG1 with EGFR has been further studied in a recent manuscript
showing LRIG1 was also able to couple with EGFRvIII, a mutant EGFR with exons 2–7
deleted resulting in the extracellular domain deletion, and subsequent downregulation of
the receptor. Results from this study indicated that LRIG1 can interact with EGFR either
via the extracellular or the transmembrane domain (Stutz, Shattuck et al. 2008).
LRIG1 not only interacts with EGFR. Ectopic expression of LRIG1 suppresses the
expression of each of the EGFR family proteins. Interestingly however, there was no
downregulation in the expression of fibroblast growth factor receptor and nerve growth
factor receptor, indicating this effect is specific to EGFR family proteins (Gur, Rubin et al.
2004).Chapter 1. Introduction
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Figure 1.4 LRIG1 facilitates EGFR ubiquitylation
C-Cbl binds to EGFR in a phosphorylation-dependent manner, whilst to LRIG1 in a
phosphorylation-independent manner (Rubin, Gur et al. 2005). In addition to the
recruitment of c-Cbl by EGFR itself, LRIG1 introduces c-Cbl to activated EGFR. C-Cbl
is phosphorylated by activated EGFR and then capable of directing EGFR ubiquitylation.
(Adapted from Segatto et al. 2011)
LRIG1 and Cancer
The LRIG1 gene maps to chromosome 3p14, a region frequently deleted in human
tumours, which indicates the role for LRIG1 in tumour suppression. As a consequence of
the EGFR suppression, proliferative inhibition of various cells has been shown by ectopicChapter 1. Introduction
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LRIG1 expression, including such as human embryonic kidney-293 cells (Gur, Rubin et al.
2004), NIH3T3 fibroblasts (Laederich, Funes-Duran et al. 2004), keratinocytes (Jensen
and Watt 2006), bladder carcinoma cells (Yang, Yan et al. 2006), and prostate tumor cells
(Laederich, Funes-Duran et al. 2004). Concordantly, LRIG1 has been reported
downregulated in skin cancer (Jensen and Watt 2006), renal cell carcinoma (Thomasson,
Hedman et al. 2003) and squamous cell lung carcinoma (SCC) (Boelens, van den Berg et
al. 2009), which have been associated with upregulated EGFR signalling.
LRIG1 and Tissue Homestasis
LRIG1 also plays a role in epidermal homeostasis with the Lrig1-defective mouse model
generating in epidermal hyperplasia and psoriasiform epidermal hyperplasia (Suzuki,
Miura et al. 2002). Jensen et al. used the same murine model to demonstrate
Lrig1-expressing cells in epidermis are a multipotent stem cell population. LRIG1 seems
to regulate epidermal stem cell quiescence by downregulating EGFR and decreasing
cMyc, resulting in the balance of proliferation and differentiation (Jensen, Collins et al.
2009). The same group knocked-down LRIG1 in cultured human keratinocytes, and found
the expansion of stem cell population contributing to the increase of cell proliferation
(Jensen and Watt 2006).
1.3.5.2.5 E-cadherin
E-Cadherin is a calcium dependent cell adhesion protein expressed predominantly in
epithelial tissues (Andl and Rustgi 2005). The mechanism of E-cadherins interaction with
EGFR is poorly understood despite its likely biological importance in epithelialChapter 1. Introduction
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homeostasis and control of proliferation at cell-cell contact. It has been demonstrated that
the EGFR family inhibit E-cadherin resulting in epithelial mesenchymal transitions (EMT)
(Fujita, Krause et al. 2002; Thiery 2002). In addition to that, E-cadherin has also been
reported as an inhibitor of EGFR family (Qian, Karpova et al. 2004). By using cultured
MDCK (Madin Darby Canine Kidney) cells, Qian et al. tested EGFR activity at both low
and high culture density. They found no EGFR activity upon EGF stimulation at high
density culture, whilst low density cells with little surface E-cadherin activate the EGFR
signalling. They used a forced-ErbB2 expression cell model to further demonstrate that
E-cadherin inhibits EGFR signalling by lowering the ligand binding affinity rather than
preventing dimerisation. An E-cadherin/EGFR complex was found in their MDCK cells,
and the complex seemed unstable in low calcium conditions or in the presence of
E-cadherin neutralising antibody, indicating the effects of E-cadherin on EGFR are
adhesion dependent therefore underscoring the importance of contact inhibition.
1.3.6 EGFR and epithelial repair
EGFR and its ligands are detected at low levels in conducting airway epithelial cells.
In a study using naphthalene injury mouse model, EGFR was found increased in distal
bronchioles immediately after injury (1 to 2 days), decreased slightly 4-7 days after injury
and back to basic line 14-21 days after injury. The pattern of EGFR was reflected in the
corresponding changes of BrdU staining, but not corresponded to the pattern of the EGF
and TGF- expression, suggesting the cell proliferation is modulated at receptor level
(Van Winkle, Isaac et al. 1997). Indeed, EGFR hyper-expression and activation in airway
epithelium has been shown increased in response to various stimuli including TNF-Chapter 1. Introduction
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(Takeyama, Dabbagh et al. 1999), mechanical damage (Lee, Takeyama et al. 2000),
cigarette smoke (Takeyama, Jung et al. 2001), and inhalation of noxious product (Madtes,
Busby et al. 1994). EGFR activation is thought to be ligand-dependent. Although some
early studies reported the ligand-independent EGFR occurred in response to oxidative
stress caused by cigarette smoke, however, these stimuli can induce EGFR proligand
shedding from the epithelial cell surface and subsequent ligand binding to the receptor.Chapter 1. Introduction
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1.4 The Wnt/-catenin signalling pathway and its role in airway
epithelial homeostasis and repair
1.4.1 The Wnt/-catenin signalling pathway
The Wnt proteins are a family of around 19 secreted glycolproteins (Konigshoff and
Eickelberg 2010). They are involved in cell-cell signalling and have been shown to effect
cell fate decisions and proliferation (Dale 1998). They exert their action on cells via three
main pathways: the planar cell polarity pathway, which is involved in the organization of
epithelial cells; the Wnt/Ca2+ pathway and the “canonical” pathway involving -catenin
(Konigshoff and Eickelberg 2010). In the canonical pathway, when a cell is stimulated by
Wnt ligands, -catenin mediated signalling is activated.
-catenin is a cytosolic protein containing approximately 100 amino acids (Huber, Nelson
et al. 1997). It can be found in two cellular locations: plasma membrane acting as an
essential component of cell-cell adhesion (shown in Figure 1.5), and cytoplasm playing an
important role in signal transduction of the Wnt pathway (Case and Rubin 2010).Chapter 1. Introduction
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Figure 1.5 The involvement of -catenin in cell-cell adhesion.
Cadherins including E-, P-, N- and VE-cadherin are bound with P120 which, in turn binds to
-catenin, the latter binds to actin via -catenin. This complex effectively forms a link between
cadherin and the actin cytoskeleton.
In the non Wnt stimulated cells, cytoplasmic -catenin has a very short half-life as its
breakdown is rapidly initiated by the complex shown in Figure 1.6. Once phosphorylated
by the degradation machinery, -catenin is marked out for ubiquitination and then
degraded by proteasomes. It is thought that the GSK3 component of the degradation
machinery is responsible for phosphorylation of -catenin (Behrens 2000). When the
concentration of cytoplasmic -catenin is high, GSK3 can act to phosphorylate parts of
APC which increases the phosphorylation and therefore degradation of -catenin
(Rubinfeld, Albert et al. 1996). Therefore, in the nucleus, prospective target genes of the
pathway are kept in a repressed state.Chapter 1. Introduction
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Figure 1.6 The breakdown of cytoplasmic -catenin
In the absence of Wnt, cytoplasmic -catenin is phosphorylated by a complex of glycogen
synthase kinase 3 (GSK3), axin (also known as conductin) and adenomatous polyposis coli
(APC), follow by ubiquitylation targeted by -transducin repeat containing protein (TrCP) and
subsequent degradation by the proteosome.
When the frizzled receptor is activated it is thought that, through interaction with low
density lipoprotein receptor-related protein 6 (LRP6) and dishevelled proteins, -catenin
is prevented from being phosphorylated by the axin/GSK3/APC complex, see Figure 1.7.
The exact mechanism for this inhibition is unknown but it most likely involves axin
binding to the LRP6/frizzled/dishevelled complex at the cell membrane, thereby reducing
the availability of axin to form the degradation machinery (MacDonald, Tamai et al.
2009).Chapter 1. Introduction
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Figure 1.7 Canonical-catenin signalling pathway.
With the presence of Wnt ligands, the “frizzled” G-protein coupled receptor is activated and
induces a phosphorylation cascade involving the disheveled family proteins (dsh) which recruits
axin to plasma membrane, resulting in the destruction of the degradation machinery. Therefore
-catenin escapes the phosphorylation and subsequent degradation and accumulates in
cytoplasm. The active -catenin translates to the nucleus where it interacts with transcription T-cell
factor (TCF) and lymphoid enhancer factor (LEF) to cause transcription of target genes.
As a consequence, the -catenin is increased in the cytoplasm. Which is then able to
translocate into the nucleus where it can interact with the transcription factors of the TCFChapter 1. Introduction
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family (TCF1, TCF3, TCF4 and LEF1) (Arce, Yokoyama et al. 2006). There are a large
variety of transcription targets of the -catenin/TCF or -catenin/LEF complex including
c-myc and cyclin-D1 (Behrens 2000) which are important for cell proliferation and
regulation of cell cycle progression respectively (Alao, Gamble et al. 2006).
-catenin has also been implicated in the genesis of epithelial mesenchymal transitions
(EMT). This is when epithelial cells invade their basement membrane becoming invasive
and mobile. The mechanism for this is thought to involve the products of some -catenin
transcription targets such as Slug and Twist, which inhibit the E-cadherin promoter; and
L1, which inhibits E-cadherin. EMT is also thought important in the formation of tumor
metastases (Heuberger and Birchmeier 2010).
1.4.2 The role of -catenin in the epidermis – clues to the respiratory
epithelium?
The role of -catenin in the epidermis of mice has been well studied. This information
could be useful when investigating the role of -catenin in the trachea. In vitro, -catenin
was found to increase proliferation of epidermal stem cells by almost 90% whilst cells
expressing a dominant negative mutation were found to exit the stem cell compartment
entirely (Zhu and Watt 1999). These stem cells are also known to express high levels of
cytoplasmic -catenin in vivo (Lo Celso, Prowse et al. 2004).
In vivo experiments (Lo Celso, Prowse et al. 2004) using transgenic mice, which express
stabilised cytoplasmic -catenin under the control of Keratin 14 (K14) promoter, showedChapter 1. Introduction
37
that the increased cytoplasmic -catenin induced hyperproliferation in both hair follicle
and skin. Niemann et al. explored the epidermal phenotype of a transgenic mouse model
which lacked the -catenin binding site in LEF1 under the control of K14 promoter,
leading to inhibition of -catenin-dependent transcription in target cell compartment.
These mice were born with normal skin, however after six weeks they began to lose hair
and develop epidermal cysts. Adult mice developed spontaneous sebaceous skin tumors
(Niemann, Owens et al. 2002).
These studies demonstrate that -catenin is not a simple on/off signalling mechanism and
that the level of catenin can regulate cell fate decision and proliferation in the
epidermis.
1.4.3 The role of -catenin in the lung
It has been demonstrated that canonical Wnt/-catenin pathway is active in the
development of the murine lung epithelium (Konigshoff and Eickelberg 2010). Mucenski
et al. investigated the role of -catenin in the developing lung by using a transgenic mouse
model which expresses an activated form of -catenin. At birth, lung morphogenesis was
not seen to be affected, although in the early post-natal period the mice developed air
space enlargement and epithelial cell dysplasia. In the adult transgenic mice goblet cell
hyperplasia was noted and some mice developed pulmonary tumors (Mucenski, Nation et
al. 2005). The same group investigated the effect of the deletion of -catenin on the
developing lung, the mice died at birth. Although the proximal airways were found to
have developed normally in these mice, peripheral airway epithelium had failed toChapter 1. Introduction
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develop correctly and resembled proximal airway epithelium (Mucenski, Wert et al.
2003).
To investigate the role of -catenin on adult murine lower airway epithelium, Reynolds et
al. used a transgenic mouse model with an activated form of -catenin under the control
of the Clara cell secretory protein (CCSP) promoter, which resulted in the increased
expression of cytoplasmic -catenin in Clara cells. In the steady state, there is no
significant difference in the proliferative index of the epithelium in these mice, whilst
after epithelial injury the transgenic mice were able to repair faster than the WT mice in
response to the Clara cell-specific toxicant naphthalene, which may attribute to the
amplification of variant Clara cells (Clara cells deficient in cytochrome P450-2F2
therefore resistant to naphthalene ), thought to be bronchiolar stem cells (Reynolds,
Zemke et al. 2008).
The effect of -catenin deletion in murine bronchioles was investigated by Zemke et al. It
was noted that although diffuse -catenin signalling was present in the steady state
bronchiolar epithelium of WT mice, the knockout mice showed no difference in
proliferation. After airway injury, the knockout mice were able to restore their ciliated cell
population to the same degree as the WT mice, so it was concluded that -catenin was not
necessary for the maintenance or repair of the murine epithelium (Zemke, Teisanu et al.
2009). However due to a relatively small sample size (n=3), this result remains
inconclusive.Chapter 1. Introduction
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1.4.4 The Wnt/-catenin pathway in cancer
Mutations in many different proteins involved in the canonical -catenin signalling
pathway have been shown to be present in a variety of human cancers. Up to 80% of
colon tumors have been found to have APC mutations and in those tumors without APC
mutations, almost 50% have activating -catenin mutations (Paul and Dey 2008). Axin
mutations have been shown in oesophageal squamous cell carcinoma (Nakajima, Fukuchi
et al. 2003). These mutations, although occurring in different proteins of the signalling
pathway, may prevent -catenin from being phosphorylated, allowing it to enter the
nucleus and act to increase the transcription of the target genes previously described –
probably one step in the multi-step oncogenic process that can eventually lead to cancer
formation.
In the lung, cancer cells over expressing Wnt-1 were induced to apoptose with the
antibody to Wnt-1. The same antibody also suppressed tumor growth in vivo (He, You et
al. 2004). It has also been shown that dishevelled overexpression is present in a number of
NSCLC and this could lead to activation of -catenin signalling and encourage tumor
growth NSCLC (Uematsu, He et al. 2003). These studies serve to show the potential
importance of -catenin and Wnt signalling in the development of lung cancer.Chapter 1. Introduction
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1.5 Summary
Both EGFR and Wnt/-catenin pathway have been demonstrated involved in human
tumorigenesis; however, whether they initiate or accelerate this process remains
inconclusive. Various animal experiments have investigated their role in bronchi and
bronchioles epithelial repair and homeostasis (Wnt/-catenin pathway), but the data
referring to the murine upper airway, a closer model to human airway, is still rare. I
therefore wished to study murine tracheal homeostasis and the role of these pathways, and
examine their relevance to early lung cancer.
1.6 Hypothesis
LRIG1 plays a role in murine upper airway epithelial homeostasis by inhibiting EGFR
pathway.
Wnt/-catenin pathway regulates murine upper airway epithelial homeostasis and repair.
1.7 Aims
1. Using transgenic mice I will determine the effects of downregulated/upregulated
signalling on tracheal epithelial proliferation and differentiation
2. I will manipulate the target pathways in vitro to investigate their roles in murine andChapter 1. Introduction
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human epithelial cell proliferation and differentiation
3. Using biopsy samples of human pre-invasive lung cancer lesions I will examine the
pathways relevance to cancer developmentChapter 2. Materials and Methods
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CHAPTER 2. MATERIALS AND METHODS
2.1 Cell Biology
2.1.1 General chemicals, solvents and plastic ware
All chemicals were of analytical grade or above and were obtained from Sigma Aldrich
(Poole, UK) unless otherwise stated. All water used for the preparation of buffers was
distilled and deionised (dH2O), using a Millipore water purification system (Milipore
R010 followed by Millipore Q plus; Millipore Ltd., MA, US). Polypropylene centrifuge
tubes and pipettes were obtained from Becton Dickenson (Oxford, UK).
All sterile tissue culture media, sterile tissue culture grade trypsin/EDTA, tissue culture
antibiotics and fetal bovine serum (FBS) were purchased from Invitrogen (Paisley, UK)
unless otherwise stated. Sterile tissue culture flasks and plates were obtained from Nunc
(Roskilde, Denmark) unless otherwise stated.
Phosphate buffered saline
8 g NaCl, 0.35 g KCl, 1.43 g Na2HPO4 and 0.25 g KH2PO4 were dissolved in 1L ddH2O,
adjusted to pH 7.2 and autoclaved.Chapter 2. Materials and Methods
43
Polybrene Stock solution
100mg polybrene powder (Sigma) was dissolved in 20 ml PBS to produce a concentration
of 5 mg/ml (1000x stock). The stock solution was sterile filtered through a 0.22 mm filter,
aliquoted and stored at –20
oC.
Tris Buffered Saline (TBS)
10x Stock solution was prepared by dissolving 24.2g Tris base and 80g NaCl in 1LdH2O.
The pH was adjusted to 7.6 and the solution was sterile filtered.
Mitomycin C stock solution
Mitomycin C is an inhibitor of DNA synthesis and nuclear division. It is used to
metabolically inactivate J2-3T3 cells to form a feeder layer for the culture of primary
keratinocytes. A 100x stock solution was prepared by dissolving 4 mg of mitomycin C
powder (Sigma) in 10 ml PBS. The final concentration used was 4 mg/ml.
Puromycin Stock solution
10 mg/ml puromycin solution (Sigma-Aldrich, p9620) was diluted in sterilised PBS, to
give a concentration of 1mg/ml
2.1.2 Cultured cell types
A549 cells are Human lung adenocarcinoma epithelial cell line. H357 cells are human
oral squamous cell carcinoma in nature. BEAS-2b cells are established normal human
bronchial epithelial cells. iHBECs are immortalized human bronchial epithelial cells.Chapter 2. Materials and Methods
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J2-3T3 cells were used as feeder cells for supporting epithelial cells growth. Murine
tracheal epithelial cells were isolated from adult mice and grown as described below.
A549, H357 and J2 3T3 feeder cells were obtained from Cancer Research UK, London
Research Institute (CRUK, London, UK). BEAS-2b cells were a kind gift from Dr. Chris
Scotton in the host laboratory. iHBECs were a kind gift from Dr Gisli Jenkins (University
of Nottingham) (Vaughan, Ramirez et al. 2006). AM12-empty vector (EV), AM12-LRIG1
cells were kind gifts from Dr Kim Jensen, Cancer Research UK, London Research
Institute (CRUK, London, UK).
All cells were under mycoplasma screen in host laboratory on a regular basis. If any
mycoplasma contamination was detected all of those cell stocks were disposed of.
2.1.3 Culture of human cells
All cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) with 4mM
L-Glutamine, 50U/ml penicillin and 50g/ml streptomycin and 10% (v/v) fetal bovine
serum (FBS) and incubated at 37°C in a humidified, 5% CO2 atmosphere, unless
otherwise stated.
iHBECs were cultured in Keratinocyte-SFM, supplemented with L-glutamine, EGF and
BPE and antibiotic. (invitrogen, #17005-075). H357 cells were cultured in a 1:3 mix of
Hams F12 medium and DMEM. In addition to FBS, L-Glutamine, and antibiotics, this
medium was supplemented with 10
-10M cholera enterotoxin (ICN Pharmaceuticals Ltd.,
Oxon, UK), 0.5g/ml hydrocortisone, 10ng/ml epidermal growth factor, and 5g/mlChapter 2. Materials and Methods
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insulin.
Medium was changed every 3 days. Cells were grown until approximately 80% confluent
and then mobilised by washing with autoclaved phosphate-buffered saline (PBS) followed
by 18l/cm
2 of 0.05% trypsin in EDTA. The H357 and iHBECs cells would not detach
efficiently using this technique and hence they were washed and then incubated in
Versene (invitrogen #15040-033) for 5 minutes at 37°C before trypsinisation as above.
After detachment, cells were spun and passaged into tissue culture flasks at ratios of 1:3 to
1:8 every 3 – 10 days depending on rate of proliferation.
2.1.4 Freezing and thawing of cells
Cells were harvested as above then resuspended in 50% (v/v) medium, 40% (v/v) FBS
and 10% (v/v) DMSO. 1ml aliquots were then frozen in each cryovial overnight at –70˚C 
in insulated containers. One 75 cm
2 flask was aliquoted into 3-5 cryovials. The vials
were then transferred to liquid nitrogen storage. Thawing of cells was performed by
transferring cryovial tubes to a 37˚C water bath.    As soon as the cell suspension was 
thawed it was added to 10ml of medium and centrifuged at 1,000 rpm for 5 minutes.
The cells were then resuspended in medium and plated onto 75 cm
2 flasks.Chapter 2. Materials and Methods
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2.1.5 Culture of mouse tracheal epithelial cells
2.1.5.1 Media or solution
FAD 200ml
Volume Ingredient Final Conc.
100ml DMEM -
100ml F12/kinght
2ml Pen/Strep
2ml L-glutamin
Pronase (0.15%=1.5mg/ml); make fresh and filter: 0.0015g=1.5mg
Volume Ingredient Final Conc. Source/Cat no.
15mg Pronase I 0.15% Boehringer no.
165921
10ml FAD - -
DNase solution (0.5mg/ml) filter and store at –20
oC
Volume Ingredient Final Conc. Source/Cat no.
10mg Crude pancreatic DNase I 0.5mg/ml Sigma no.
DN-25
2ml BSAstock (10mg/ml) 0.666mg.ml -
18ml FAD - -Chapter 2. Materials and Methods
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Retinoic acid stock A5x10
-3M (dissolve in the dark);filter and store at –80
oC
Volume Ingredient Final Conc. Source/Cat no.
50mg Retinoic acid powderA 5x10
-3M Sigma no.
DN-25
33.3ml 95% ethanol -
Retinoic acid stock B 5x10
-6M ; filter and store at –80
oC, store up to 4weeks
Volume Ingredient Final Conc. Source/Cat no.
50ul Retinoic acid stockA 5x10
-6M
500ul OR
50mg
BSAstock (10mg/ml) 1mg/ml -
49.45ml HBBS - -
MTEC/Basic (stable for 1-1.5 months)
Volume Ingredient Final Conc.
200ml FAD - 39.24ml 19.62ml
0.8ml 0.1M NaHCO3(filter) 0.4mM 160ul 80ul
3.0ml 1M HEPES pH7.2 (filter) 0.015M 600ul 300ul
MTEC/Basic +NuSerum + RA.Use immediately once RAadded.
Ingredient Final
Conc.
Source/Cat
no.
Volume
MTEC Basic - - 38.8ml 19.4ml
NuSerum 2% BD no 0.8ml 0.4mlChapter 2. Materials and Methods
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51000
Retinoic Acid
stock B (100x
stock)
10
-8 M Sigma no.
R2625
0.4ml 0.2ml
NuSerum must be heat inactivated for 20mins at 56C prior to use in order to get rid of
complement.
MTEC/PLUS (stable 1-2 weeks)
Volume Ingredient Final Conc. 40ml 20ml
200ml FAD - 36.68ml –
BPE volume
18.34ml –
BPE volume
0.8ml 0.1M NaHCO3 (filter) 0.4mM 160ul 80ul
3.0ml 1M HEPES pH7.2
(filter)
0.015M 600ul 300ul
0.4ml Insulin (5mg/ml) (filter) 10ug/ml 80ul 40ul
0.4ml TEC (filter) 500x stock - 80ul 40ul
0.5ml BPE current batch
11.5mg/ml
0.03mg/ml varies varies
10ml FBS 5% 2ml 1ml
TEC=transferrin, EGF, Cholera toxin.
BPE= Bovine Pituitary Extract (invitrogen 13028-014)
Insulin = sigma I6634Chapter 2. Materials and Methods
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MTEC/PLUS+RA use immediately
Ingredient Final Conc. 20ml 40ml
MTEC/PLUS - 19.8ml 39.6
Retinoic acid,stock B 100x
stock
10
-8 M 0.2ml 0.4ml
2.1.5.2 Isolation of primary MTECs
Mouse Tracheal Epithelial Cells (MTECs) were harvested as previously described (You,
Richer et al. 2002). Mice were sacrificed by sodium pentobarbitol overdose, and then
briefly immersed in 70% ethanol (avoiding airway submersion), followed by cutting open
peritoneal cavity and exsanguinations. With the use of a sterile technique, tracheas were
resected from the larynx to the carina. Expose trachea with vertical incision in neck, cut
open ribcage and remove salivary glands. Blunt dissect (by using outside edge of scissors)
under the trachea to get it loose from the underlying tissue.
Tracheas were placed in FAD medium, + Ca
2+, no serum and dissect away excess tissue
with tweezers under microscope. Tracheas were placed in new tube with FAD containing
1.5mg/ml Pronase (Roche) for 18 hours at 4
oC. The tube was then put on ice, and FBS
was added to a final concentration of 10%. The tracheas were inverted 10 times,
transferred to another tube of FAD medium with 10% FBS, inverted again. Repeated
twice for total of 4 tubes, then combined media and discard tracheas. Contents of the four
tubes were pooled and collected by centrifugation at 300 g for 10mins at 4
oC. Cells were
resuspended in 5mls DNAase solution and incubated on ice for 5mins, centrifuged atChapter 2. Materials and Methods
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300g for 5 mins at 4
oC, and then resuspended in 5ml MTEC basic media with 10% FBS.
After incubation in MTECs/Basic medium (Table 2) in tissue culture plates for 2 hours in
5% CO2 at 37
oC to adhere fibroblasts, nonadherent cells were collected by centrifugation,
resuspended in 200ul MTEC/Plus (Table 3) per trachea, and counted. Cell viability
determined by trypan blue exclusion was >90%.
2.1.5.3 Pre-coating transwell dishes
Prior to cell seeding, transwell dishes were coated collagen-coating solution (recipe as
below). With lid off, dishes were allowed air dry overnight in tissue culture hood. Before
cell seeding, dishes were washed with PBS and MTEC/Basic.
Collagen-coating solution; filter and store at 4
oC up to 4weeks
Ingredient Final Conc. Source/Cat no.
rat tail collagen, type 1 50 ug/ml B/Dickinson 354236
Diluted in PBS -
2.1.5.4 Culture of MTECs
Enzyme isolated cells were counted and seeded in 12-well Transwell dishes (Corning) at
2x10
5cells/well in MTEC/plus, supplemented with Retinoic Acid (RA). Media was filled
in both upper and lower compartments. Cells were incubated at 37°C in a humidified, 5%
CO2 atmosphere. Media was changed on day 3 after seeding then every the other day
onwards. Upon visually reaching confluence (usually day 9 post-plating), media in upperChapter 2. Materials and Methods
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compartment was removed and that in lower compartment was changed to MTEC/basic
plus retinoic acid and Nuserum to enhance differentiation at an air-liquid interface (ALI)
(You, Richer et al. 2002). Media was changed every the other day. Cells were harvested at
indicated time points and subjected to immunostaining and immunoblotting. BrdU was
added 3 hours before cells fixation (ZYMED 00-0103: in vitro exp concentrated reagent
1:100 in culture media). In some experiments, cells were incubated overnight with
MTEC/Basic medium with no growth factors.
2.1.6 Retroviral infection ofA549 and H357 cells
A549 and H357 cells were transduced with pBabePuro-Lrig1Flag and pBabe Puro-EV.
Stably transduced AM12 cells were kind gift from Fiona Watt, CRUK, UK, and were
cultured with 2.5 μg/ml puromycin. One day prior to transfection, target cells were plated
in T75 flask to be transduced at 25-40% confluence. In the meantime, 4.5ml fresh
medium was added (which the target cells grow in) to transduced AM12 cells (50-75%
confluence), without puromycin, and leave it overnight. On the next day, virus containing
supernatant was collected from AM12 flask and passed through a 0.45mm syringe filter to
get rid of cell debris, followed by adding 5μg/ml polybrene to virus (from 1000 x stock). 
Medium in target cells was removed and replaced with virus + polybrene. Target cells
with virus containing supernatant then were incubated for 24 hrs. At the due time,
removed virus containing medium and rinse once with fresh medium, then added fresh
growth medium without polybrene. 48 hrs after this point, cells were split 1:4 into
selection medium (growth medium contained 2.0mg/ml puromycin final concentration).
Selection usually took 3 days. The success of the transduction was confirmed byChapter 2. Materials and Methods
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immunofluorescent staining or immunoblotting with a Flag1 antibody.
Figure 2.1 Diagram below indicating LRIG-Flag subcloning into pBabePuro
vector.
2.1.7 Manipulation of cultured cells
The inhibitors of signalling molecules used to manipulate murine epithelial cells activities
are listed below.
SB415286 was administered to either MTECs on day 3 of the culture, or iHBECs at about
50% confluence, till the harvest time point. DECMA-1 was administered to MTECs right
afterALI was achieved till the harvest time point.Chapter 2. Materials and Methods
53
Table of Inhibitors
Compound Target molecule/s Working
concentration
Source/references
SB415286  GSK-3  10 μM. 
30 μM. 
Sigma (Cross,
Culbert et al. 2001)
DECMA-1 Extracellular
domain of
E Cadherin
12 µg/ml Abcam (ab11512)
(Hordijk, ten
Klooster et al. 1997)
2.1.8 Calcium-switch experiment inA549-LRIG1 cells
It has long been established that Ca
2+ plays an important role in cell adhesion through the
interaction with E-cadherin without altering protein synthesis. I used a calcium-switch
technique (Tobey, Argote et al. 2004) to create an E-cadherin functional depletion model
in cultured A549-LRIG1 cells. Cells were plated out in chamber slides and grown until
confluence. Cells were exposed to Ca
2+ free, EDTA containing solution for 2 hr in 5%
CO2. Cells were then fixed and immunofluorescence stained (as described under relevant
section).Chapter 2. Materials and Methods
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2.2 Assays of proliferation
2.2.1 BrdU labelling cells
Human cells were cultured in chamber slides, and MTECs were cultured in transwell
dishes. Cells at targeted confluence level (50%-60% confluence; or >90% confluence)
were incubated with growth medium containing BrdU labelling solution (ZYMED
00-0103: 1:100 into growth medium) for either 1 hour (for human cells) or 3 hours (for
MTECs). Cells were fixed with 4% PFAand ready for immonofluorescent staining.
2.2.2 Colony formation efficiency assays
300 or 500 A549, H357 and BEAS-2bs, 10,000 MTECs were plated per well in 6-well
plates and cultured on a J2 3T3 feeder layer. After 14 days growth, feeder cells were
washed off with PBS and versene, then fixed with 3% (w/v) paraformaldehyde (PFA) and
followed by staining with 1% Rhodamine Blue for 20 minutes. The number of colonies
2mm or larger in diameter were counted and expressed as a percentage of the original 100
cells plated to give the percentage colony forming unit (Reynolds, Zemke et al. 2008)..Chapter 2. Materials and Methods
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Preparation of J2-3T3 cells as feeder cells
The colony formation efficiency assay requires co-cultivation with mitotically inactive
J2-3T3 cells which are referred to as feeder cells (Rheinwald and Green, 1975). Feeder
cells  were  incubated  with  4µg/ml  mitomycin  C  for  2-3  hrs  at  37˚C.  Cells  were  then 
harvested and plated onto flasks as described earlier. Cells from a confluent 75 cm2
flask were placed onto one 12-well plate. J2-puro cells were used as feeder cells during
colony forming assay.
2.2.3 Flow cytometric cell cycle analysis
One of the obvious features of the cell cycle is the synthesis and duplication of nuclear
DNA before division. By measuring DNA content in cells with
4',6'-diamidino-2-phenylindole (DAPI) staining and deconvolution of the cellular DNA
content frequency histograms, this approach reveals distribution of cells in three major
phases of the cycle (G1 vs S vs G2/M).
This experiment was performed by Dr Adam Giangreco. The following method used for
DAPI staining is modified from (Giangreco, Jensen et al. 2009).
Cell pellet was suspended in 1 mL of DAPI staining solution (0.1% (v/v) Triton X-100
and 1 μg/mL DAPI in PBS). Samples were kept in the dark, at room temperature, for 10 
min. Samples were transferred to the flow cytometer and measure cell fluorescence.
Maximum excitation of DAPI bound to DNAis at 359 nm, and emission is at 461 nm.Chapter 2. Materials and Methods
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For fluorescence excitation, use the available UV light laser line at the wavelength nearest
to 359 nm. When a mercury arc lamp serves as the excitation source, use a UG1 excitation
filter. Acombination of appropriate dichroic mirrors and emission filters should be used to
measure cell fluorescence at wavelengths between 450 and 500 nm.
All data was obtained using an LSR II flow cytometer (BD Biosciences) and analyzed
with Flowjo.
2.3 Animal experiments
2.3.1 Animals
2.3.1.1 Mouse husbandry and experimentation
Adult, 2-4 month old mice (or 2-6 month old mice for -catenin experiment) were used
for experiments, housed in individually ventilated cages on a 12 hour light / dark cycle
and allowed access to food and water ad libitum. All in vivo experiments involved a
minimum sample size of 5 animals per group, were repeated at least twice, and were
performed under the terms of a UK Home Office project license.Chapter 2. Materials and Methods
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2.3.1.2 Lrig1 experiments
Lrig1-null mice were a kind gift from Sathoshi Itami (Suzuki, Miura et al. 2002). All
transgenic mice were maintained on a mixed background of 129, C57/Bl6, and CD1
inbred strains. Homozygote deleted LRIG1 mice were compared to sex-matched
littermate heterozygote LRIG1 mice as controls.
2.3.1.3 -catenin experiments
Transgenic K14-dnLef1 and K14-∆ -cateninER mice were provided by Prof. Fiona Watt
and generated as previously described (Niemann, Owens et al. 2002); (Silva-Vargas, Lo
Celso et al. 2005);(Lo Celso, Prowse et al. 2004). TOPgal -catenin reporter mice were
obtained from a commercial vendor and generated as previously described (DasGupta and
Fuchs 1999) (Jackson Labs, Maine). All transgenic mice were maintained on a mixed
background of 129, C57/Bl6, and CD1 inbred strains.
K14-∆ -cateninER mice
These mice express a mutated form of -catenin which has a truncated N-terminal, this
prevents it from being phosphorylated by the degradation machinery previously discussed.
This truncated form of -catenin is under the control of the cytokeratin-14 (K14)
promoter and is fused to the ligand binding domain of a mutant oestrogen receptor. The
transgenic mice therefore express normal -catenin at normal levels until the transgenic
region is activated by the binding of 4-hydoxytamoxifen (4OHT) to the mutated oestrogenChapter 2. Materials and Methods
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receptor. As a consequence, a large amount of stabilized -catenin is expressed. The D2
mouse has a copy number of 12∆ -cateninER whilst the D4 mouse has a copy number of
21.
Figure 2.2 Diagram representing the K14 expression cassette and
-cateninER transgene. (Adapted from Lo Celso et al 2004)
K14-dnLef1 mice
An N-terminally deleted mouse Lef1 cDNA (lacking amino acids 1 to 32, which contain
the -catenin-binding site) was Myc-tagged at the N terminus and inserted into the blunt
ended BamHI site of the keratin 14 expression cassette. The resulting construct was
designated K14-dNLef1, which lacks the -catenin binding site, under the control of the
K14 promoter. These transgenic mice therefore overexpress dNLef1in K14-positive cells,
leading to inhibition of -catenin-dependent transcription in target cell compartment.
Figure 2.3 Diagram showing the K14-dnLef1 transgene construct.
(Adapted from Catherin Niemann1 et al 2002)Chapter 2. Materials and Methods
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TOPgal reporter mice
These TOPgal transgenic mice are a reporter strain that express beta-galactosidase in the
presence of the lymphoid enhancer binding factor 1/transcription factor 3 (LEF/TCF)
mediated signaling pathway and activated -catenin. They were maintained on an outbred
CD1 background.
Figure 2.4 Diagram showing TOPgal construct
The promoter contains three consensus LEF-1/TCF-binding motifs (L) and a minimal c-fos
promoter to drive transcription of the lacZ gene encoding -galactosidase.
2.3.1.4 Acute Tracheal epithelial injury model
For experiments involving tracheal repair, mice were anaesthetised with isofluorane and
tracheas damaged via oropharyngeal instillation of 15 µl 2% polidocanol (Sigma, UK).
BrdU was injected intra-peritoneally (Zymed 00-0103; 100ml concentrated reagent per
10g body weight, intra-peritoneally, 2 hours pre sacrifice). For -catenin experiment,
tamoxifen (solution 40mg/ml in corn oil) was injected intra-peritoneally (5mg per 20g
body weight) daily for 3 days before polidocanol was administered.Chapter 2. Materials and Methods
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2.3.2 Genotyping of transgenic mice
2.3.2.1 Ear snip digestion
Mice ear snip samples were added into 50ul buffer as below and digested at 55
oC. After 1
hour samples were vortexed and further digested for 2 hours. Then 150µl double distilled
water was added, and heated in a hot block to inactivate protein kinase at 95
oC for 10mins.
Samples were then taken through one freeze/thaw cycle, mixed and spun for five minutes
at 13000 rpm to move debris to the bottom. 1µl sample was used per PCR reaction.
Ear Snip Buffer:
1M Tris pH 8.0 1.25 ml
5M NaCl 0.1 ml
10% SDS 0.25 ml
H2O 22.4 ml
(Protein kinase at 20mg/ml;Add 40µl to 960µl of ear buffer mix)
2.3.2.2 PCR conditions
Primers
Primer
Target
Reference Primer Sequence Amplicon
D4 5 (Lo Celso, Prowse
et al. 2004)
ATGCTGCTGGCTATGGTCAG 700bpChapter 2. Materials and Methods
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D4 3 (Lo Celso, Prowse
et al. 2004)
GCACACAAACTCTTCACC
dnLef1 5 (Niemann, Owens
et al. 2002)
GCTTTCCTTCATCAGGGTG 400bp
dnLef1 3 (Niemann, Owens
et al. 2002)
CTCTGAGTCCAAACCGGGC
Topgal 5 (Zemke, Teisanu et
al. 2009)
GTGGCAGCATCAGGGGAAAACCTT 476bp
Topgal 3 (Zemke, Teisanu et
al. 2009)
GAATTCCGCCGATACTGACGGGCT
PCR Ingredients
Ingredient Stock conc Quantity (µl) Final Conc
Ear snip DNA - 1 -
MgCl2 25mM Varies 2-5mM Varies 2-5mM
dNTPs 25mM 2.5µl 2.5µM
Buffer 10x 2.5 1x
5’primer 10µM 0.5 0.2nM
3’primer 10µM 0.5 0.2nM
Taq Bioline 5U/µl 0.2 -
H20 - Up to 25µl total -
D4 PCR programme
Add 2µl MgCl stock per 25µl reaction system.Chapter 2. Materials and Methods
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1 94C 4’
2 94C 30’’
3 54C 30’’
4 72C 45’’
5 REPEAT 2-4 x32
6 72C 3’
7 15C 10'
Dnlef1 PCR programme
Add 1.5µl MgCl stock per 25µl reaction.
1 94C 2’
2 94C 45’’
3 57C 45’’
4 72C 40’’
5 REPEAT
2-4
x32
6 72C 2’
7 15C 10'
2.3.2.3 Agarose gel electrophoresis
Gel separation electrophoresis was used to confirm the products were of the expected size.
The gel was prepared by dissolving 1.5% agarose (w/v) in 100 ml 1xTBE (0.045 M
Tris-Borate, 0.001M EDTA, pH 8). Ethidium bromide was added to the gel at a final
concentration of 0.5µg/ml). The gel, once solidified, was placed in a gel tank filled withChapter 2. Materials and Methods
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1xTBE running buffer. 2µl of 5 x loading buffer was mixed with 8µl of each PCR product
and run on a lane of the gel. A DNA molecular marker (marker VIII, 0.25µg/ml,
Boehringer Mannheim) was also used. The gel was run for 35 minutes at 80 volts. The
DNAbands were visualised using a phospho-imager (Fuji, FLA-3000)
2.3.3 Assays of differentiation
2.3.3.1 Fluorescence Microscopy
Cultured primary MTECs start differentiation after ALI achievement. Differentiated
MTECs were washed with PBS and fixed with 4% PFA for 10 minutes. Transwells were
stored in PBS at 4
oC for immunofluorescent staining against epithelial cell markers.
Details as described in immunological section.
Murine tracheal tissues were fixed, sectioned and immuno-stained against epithelial cell
markers. Details as described in immunological section.
2.3.3.2 Flow cytometry
Single cell suspensions were derived from mouse tracheas after overnight 0.1% pronase
digestion at 4°C and resuspened in DMEM+10%FBS to 1x10
6 cells/ml and stained for
epithelial and immune cell markers including CD45, EpCam, and GSI-4 lectin. Briefly,
cells were incubated with primary antibody in DMEM+10%FBS for 30 minutes on roller
in cold room. Cells were then washed in PBS and incubated with secondary antibody inChapter 2. Materials and Methods
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DMEM+10%FBS for 30 minutes on roller in cold room. Cells were washed with PBS,
filtered through 70mm cell strainer and DAPI added. as previously described (Rock,
Onaitis et al. 2009; Teisanu, Lagasse et al. 2009; McQualter, Yuen et al. 2010). Dead cells
were excluded on the basis of DAPI reactivity and epithelial and basal cells identified
based on cell surface EpCam and GSI-4 lectin expression. TOPgal activity was detected
by  fluorescein  di-β-D-galactopyranoside  (FDG)  staining  as  previously  described 
(Rakhmanova and MacDonald 1998).
All data was obtained using an LSR II flow cytometer (BD Biosciences). Electronic
compensation of the recording was performed to minimise overlap of emission spectra.
Samples were gated according to forward scatter and side scatter characteristics to
exclude cell debris and cell doublets. A minimum of 1x10
5 gated events was collected for
each sample analysed. Sample analysis and quantitation was performed using FlowJo
Software.
Single stained controls were used to set compensation parameters and unstained samples
used to set negative gates.Chapter 2. Materials and Methods
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2.4 Immunological Methods
2.4.1 General solutions
Paraformaldehyde solution
A 10 % solution was prepared by adding paraformaldehyde powder (BDH) to PBS and
heating at 60
0C until mostly dissolved. A few drops of 1M NaOH were added to
completely clear the solution which was then allowed to cool to room temperature before
adjusting the pH to 7.6 with HCl. The stock was aliquoted and stored at –20
0C. A 4 %
paraformaldehyde solution was used to fix cells and tissue.
Formol saline
50g NaCl and 150g Na2SO4 were dissolved in 8L of dH2O before addition of 1L of 40 %
formaldehyde. The final solution was made up to 10Land was not autoclaved.
DAPI stock solution
DAPI powder (sigma, D9542) was dissolved in ddH2O to give concentration of 1mg/ml.
Solution was aliquoted and stored at -20
oC.Chapter 2. Materials and Methods
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2.4.2 Tissue preparation
Mice were sacrificed by sodium pentobarbitol overdose and sentinel screening for
common murine pathogens were used throughout the course of these studies. Murine
tissue sections were fixed in 4% paraformaldehyde at 4°C. After 4 hours, samples were
transferred to 15% (w/v) sucrose in PBS and stored overnight at 4°C. Samples were then
washed in 30% (v/v) ethanol and transferred to 70% (v/v) ethanol. The samples were then
dehydrated through graded ethanols and embedded in paraffin wax. 3μm sections were cut 
from paraffin embedded specimens and mounted on polylysine slides (VWR,
Leicestershire, UK) for staining. Some samples were snap frozen in OCT. 5-7μm sections 
were cut from OCT embedded specimens and mounted on polylysine slides.
Human biopsy samples were obtained via fibre optic bronchoscopy with patient consent
under institutional ethical approval by my supervisor Dr Janes or his clinical team. Tissue
sections were fixed in 10% neutral buffered formalin or 4% paraformaldehyde, processed
and sectioned at 4m thickness. All human biopsy specimens were subjected to routine
histopathological diagnosis by two consultant lung histopathologists.
2.4.3 Antibodies
The primary antibodies used for immunohistochemical localization studies were Lrig1
(rabbit; kind gift from F. Watt, CRUK, Cambridge), K14 (Rabbit, ABR Biosystems), K14Chapter 2. Materials and Methods
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(LL002) (mouse IgG3; kind gift from F. Watt, CRUK, Cambridge), CCSP (goat, gift from
B. Stripp, Pittsburg University, USA), acetylated-tubulin (mouse, Sigma), Ki67 (Vector
Laboratories), Ki67(Abcam), BrdU (ICR1) (AbDserotec), ECCD1 (Sigma), or HECD1
(gift from F. Watt, CRUK, UK), flag1 (Sigma), phospho-EGFR1 (Zymed), EGFR1
(Abcam), ZO-1 (rabbit, Sigma), and Cyclin D1 (rabbit, Abcam), Muc5AC, -catenin
(rabbit, Abcam). Secondary antibodies conjugated to HRP, Alexa555, Alexa633 or
Alexa488 (invitrogen).
Antibody Specificity Dilution Species Source
Lrig1 Lrig1 (Ms) IF 1:600 Rabbit CRUK
Lrig1 IF 1:
K14 K14 (Ms) IF 1:1000
IHC 1:5000
Rabbit ABR
Biosystems
K14 (LL002) K14 (Ms) IF 1:500 Mouse CRUK
CCSP CCSP (Ms) IF/IHC
1:10000
Goat B.Stripp
acetylated-tubulin acetylated-tubulin
(Ms)
IF 1:4000
IHC 1:8000
Mouse Sigma
Ki67 Ki67 (Hu) IHC 1:1000 Rabbit Vector
Laboratories
Ki67 Ki67 (Hu, Ms) IF/IHC
1:200
Rabbit Abcam
BrdU BrdU IF/IHC
1:150
Mouse AbDserotec
ECCD1 E-cadherin (Ms) IF 1:500 Rat SigmaChapter 2. Materials and Methods
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HECD1 E-cadherin (Hu) IF 1:1000 Ms CRUK
Flag1 (M1) Anti flag fusion
proteins
IF 1:1000 Ms Sigma
phospho-EGFR1 Anti
phospho-EGFR1
IF 1:1000 Rabbit Zymed
ZO-1 Anti-ZO-1 (Hu) IF 1:1000 Rabbit Sigma
Cyclin D1 Anti Cyclin D1
(Hu, Ms)
IF 1:500 Rabbit Abcam
-catenin Anti- -catenin
(Hu, Ms)
IF 1:200 Rabbit Abcam
EGFR1 Anti-EGFR
(Hu, Ms)
ICC 1:500 Mouse Abcam
2.4.4 Immunohistochemistry
Human and murine haematoxylin and eosin (H&E) staining was performed using an
automated staining system (TissueTek).
2.4.4.1 Immunoperoxidase technique
For  immunohistochemical  staining,  3μm  sections  were  dewaxed  and  rehydrated  by 
immersion in xylene followed by decreasing concentrations of ethanol through to water.
They were then washed twice in PBS. To unmask antigenic epitopes, sections were
pre-treated by immersion in 0.01M sodium citrate and microwave heating at high powerChapter 2. Materials and Methods
69
for two consecutive periods of ten minutes. Pre-treated sections were then washed twice
in PBS. Endogenous peroxidise was blocked by immersing sections in 3% (v/v) H2O2 for
30 minutes at room temperature. Sections were then washed twice in PBS and treated
with a 1 in 6 solution of serum (matching that in which the secondary antibody was raised
e.g. goat serum for a goat anti-rabbit secondary antibody) in PBS containing 4 drops/ml of
Avidin block (Vector Laboratories) for 20 minutes at room temperature. Samples were
then drained before addition of primary antibody in 1% (w/v) BSA in PBS with 4
drops/ml of Biotin block (Vector Laboratories) overnight at 4
oC. Appropriate isotype
controls were used for each experiment. Samples were washed twice in PBS then
treated with a 1:200 dilution of biotinylated secondary antibody (Dako) in PBS 1% (w/v)
BSA for 1 hour at room temperature. Samples were rewashed in PBS before the addition
of 1:200 Streptavadin HRP (Dako) in PBS for 30 minutes at room temperature. Sections
were washed in PBS again, before 3,3-Diaminobenzidine (DAB) peroxidise substrate
(Vector Laboratories) was added for 10 minutes at room temperature. Samples were
drained, rinsed in dH2O, counterstained with Gill’s Haematoxylin, dehydrated in Xylene
and mounted on a coveraid system (Sakura Firetek, CA, US). Microscopy was
performed with an Olympus BX 40 light microscope.
The optimal pre-treatment regimen and primary antibody concentration was determined
by performing a titration with each antibody with suitable positive and negative controls.
This consisted of a range of antibody concentrations, including the recommended dilution,
and  different  antibody  unmasking  pre-treatments  including  no  pre-treatment,  10μg/ml 
Proteinase K, or microwave heating in citrate buffer. These sections were then
immunohistochemically stained and the optimal conditions selected. The microwave
heating in citrate buffer was used for pre-treatment for all the primary antibodies, unlessChapter 2. Materials and Methods
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otherwise stated.
2.4.4.2 Immunofluorescence staining– sections
For immunohistochemical staining, 3μm sections were dewaxed and washed 3 times in 
PBS. Sections then were blocked in 10%FBS/0.2% fish gel/PBS solution for 1 hr.
Samples were then drained before addition of primary antibodies in blocking solution
overnight at 4
oC. Appropriate isotype controls were used for each experiment. Samples
were washed twice in PBS then treated with secondary antibodies (1:500) for 3 hrs at
room temperature. The slides were then wash in PBS and counterstained with 1μg/ml 
DAPI for 10 minutes. Slides were washed twice in distilled water before mounting with
Immu-mount (Thermo Electron Corp., PA, US).
Images were acquired using a Leica TCS Tandem or SPE confocal or an Olympus
brightfield microscope. Confocal images were imported into Volocity software (Perkin
Elmer) for accurate measurement of intensity. Four representative z-stack images acquired
with a 40x objective were analysed for each of three animals in Lrig-null and Het groups.
All images were post-processed using Adobe Photoshop (Photomerge, rotate, crop,
brightness and contrast adjustments). Epithelial height and cell density were determined
using Volocity image analysis software. I quantified the abundance of specific tracheal
cell phenotypes as a function of epithelial basement membrane length. Cell surface
E-cadherin abundance was quantitated as previously described (El-Bahrawy, Talbot et al.
2002).Chapter 2. Materials and Methods
71
2.4.4.3 Immunofluorescence staining – cells
For staining of ex-vivo cells, the cells were cultured onto tissue culture plastic microscope
slides (Nunc). They were fixed with 4% (w/v) PFA for 10 minutes at room temperature,
washed 3 times in PBS, and permeabilised with 0.2% (v/v) Triton X-100 in PBS for 5
minutes if required. The cells were then blocked with PBS containing 10% (v/v) FBS
and 0.2% (v/v) fish gel, before application of the primary antibodies diluted in the
blocking solution overnight at 4
oC. After 3 washes, the fluorescent secondary antibodies
were applied for another 3 hours. The cells were then rewashed and 1g/ml DAPI
applied and mounted with Immu-mount. Images were acquired and analyzed as previous
describe.
2.4.4.4 BrdU cyto-immunostaining
Cells labelled with BrdU were fixed with 4% PFA for 10 minutes, and washed in PBS.
Samples were permeablised with 0.2% Triton X-100 for 5 minutes, then washed in PBS.
Samples were fixed again with 3.7% formaldehyde (concentrate formaldehyde 1:10 in
PBS) for 10 minutes, then washed in PBS. Slides were denatured DNA by incubating
sections in 2N HCL for 30 minutes at room temperature, followed by neutralising the acid
with 0.1M borate buffer (pH8.5) for 2x5 minutes. Slides were washed with PBS, and
blocked, stained as above described.Chapter 2. Materials and Methods
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Solutions for BrdU cytoimmunostaining
2N HCl
10N HCl 20ml
ddH2O 80ml
mix well
0.1M Borate Buffer, pH 8.5
Sodium borate (MW 381.4) 3.8g
ddH2O 100ml
mix to dissolve and ajust pH to 8.5
2.5 Immunoblotting
2.5.1 Reagents
RIPAbuffer 500ml
1x PBS 500ml
1% Igepal CA-630 5ml
0.5% Sodium deoxycholate 2.5ml
0.1% SDS 0.5g
10ml aliquot and freeze in -20°C.Chapter 2. Materials and Methods
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1.5M Tris-base pH 6.8 and 8.8
181.71g TRIS made up to 1Lin ddH2O.
pH with HCl.
Laemmli Buffer (x5)
312.5 mM TRIS pH 6.8 3.125ml
10% SDS 1g
20% glycerol 2ml
50mM DTT 0.5ml (add just before use)
bromophenol blue add until dark blue
make up to 10ml with ddH20
Running Buffer (X10)
0.25M TRIS base 30.3g
1.92M Glycine 144g
1% SDS 10g
make up to 1Lin ddH20
Transfer Buffer (10X) without methanol:
Glycine 2.93g
Tris 5.81g
SDS 0.375g
make up to 1Lin ddH20Chapter 2. Materials and Methods
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TBS (X10)
24.2g TRIS base
80g NaCl
make up to 1Lin ddH20 and pH to 7.6 with HCl
Stripping Buffer
10% SDS 8ml
1M TRIS pH6.8 2.5ml
ß-mercaptoethanol 280ul
Make up to 40ml with ddH20.
2.5.2 Sample collection and preparation
Cells were grown in 12-well plates to reach confluence. Cell lysates were obtained by
lysing the cells with 100µl RIPA buffer supplemented with complete protease inhibitor
cocktail (Complete-mini; Roche Diagnostics Ltd.) and phosSTOP phosphatase inhibitor
(PhosphoSafe™ Extraction Reagent Novagen). The cell layer was subsequently scraped
with a pipette tip and the lysate centrifuged (13,000 rpm, 5 mins, 4°C) to remove
insoluble cell debris. The supernatant was collected and the DNA sheered by passing the
sample 15 times through a 25G needle. Samples were stored at -80 °C.Chapter 2. Materials and Methods
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2.5.3 BCAprotein assay
To ensure equivalent amounts of protein were loaded for the different samples, protein
concentration of cell lysates or supernatants was assessed using the bicinchoninic acid
(BCA)  protein  assay  (Thermo  Fisher  Scientific,  IL,  US).    20μl  of  each  sample  or 
standard (bovine serum albumin (BSA)) was added to 200μl of BCA working reagent in a 
96-well plate. The plate was agitated on a plate shaker for 30 seconds, and then incubated
at 37°C for 30 minutes prior to reading the absorbance at 550nm on a Titertek Multiscan
MCC/340 plate reader (Labsystems, Turku, Finland). The absorbance of the samples
was compared to the standards (of known protein concentration) to ascertain the sample
protein concentration.
2.5.4 SDS-PAGE
Equal amounts of protein from each sample (typically 10-20 mg total protein) were
diluted into 5x Laemmli Buffer. 10ul 1M DTT was added to 190ul Laemmli buffer (final
DTT concentration = 50mM) unless otherwise stated. The samples were then incubated on
a heat block for 5 minutes at 100°C and placed on ice prior to loading on the western blot
gel. The table below describes the gel compositions. Immediately after pouring the
resolving gel solution, dH2O was carefully applied to level the surface. Gels were allowed
to set at room temperature for approximately 30 min. The dH2O layer was discarded from
the top of the resolving gel and the stacking gel solution was then poured. An 8 or 12 wellChapter 2. Materials and Methods
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comb was inserted to create wells and the gel was left to polymerise. After the gel had set,
the comb was removed and the wells were flushed with SDS-PAGE running buffer. After
being briefly spun down in a bench top centrifuge, samples were applied to the wells
using capillary pipette tips. 5l of SeeBlue® Plus 2 protein ladder (Invitrogen) was also
loaded. The gel was run at 100V in Tris/Glycine/SDS running buffer until the dye front
had run off the bottom of the gel and the gel was then removed and prepared for Western
blot.
Table Preparation of Tris-glycine SDS-Polyacrylamide Gel (SDS-PAGE)
Resolving gel (15ml)
Concentration 6% 8% 10% 12%
30% acrylamide mix (ml) 3 4 5 6
1.5M Tris (pH8.8) (ml) 3.75 3.75 3.75 3.75
10% SDS (ml) 0.15 0.15 0.15 0.15
10% ammonium
persulphate (ml)
0.15 0.15 0.15 0.15
TEMED (ml) 0.012 0.009 0.006 0.006
ddH20 (ml) 7.95 6.95 5.95 4.95
Stacking gel (10 ml)
30%
acrylamide
mix (ml)
1M Tris
(pH6.8)
(ml)
10% SDS
(ml)
10%
ammonium
sulphate (ml)
TEMED
(ml)
ddH20 (ml)
1.7 1.25 0.1 0.1 0.01 6.8Chapter 2. Materials and Methods
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2.5.5 Western Blotting
Following separation, the gel was removed from the cassette and proteins were transferred
onto a Hybond-ECL nitrocellulose membrane (GE Healthcare), using a horizontal
semi-dry transfer method (NovaBlot; Pharmacia LKB, Uppsala, Sweden) with 2x transfer
buffer with 20%(v/v) methanol at a current of 0.8mA per cm
2 of gel, for 1 hour. The
quality of protein transfer was assessed by briefly staining the membrane with 0.1% (w/v)
Ponceau solution and then the blot was placed in Tris-buffered saline (TBS) containing
0.1% (v/v) Tween20 (TBST).
Blots were incubated with blocking buffer containing 5% (w/v) non-fat dry milk in TBST
for 1 hour at room temperature to block non-specific binding of antibodies.
Blots were then incubated with primary antibodies in 5% (w/v) BSAin TBST overnight at
4°C with gentle agitation. All blots were then washed 3 x 5 mins in TBST and incubated
for 1 hour at room temperature with HRP-conjugated secondary antibody diluted 1:2000
in 5 % milk, TBST. Membranes were then washed 3 or 4 times with TBST. To detect
bound HRP, 1ml of ECL reagent (GE Healthcare) was applied to each membrane, and
incubated for 1 minute. Excess reagent was drained off and immunoreactive bands were
visualized by exposing the membrane to autoradiography film (Hyperfilm, GE
Healthcare), for between 30 seconds and 5 minutes. If blots were to be re-probed they
were stripped in striping buffer for 30 min at 60
oC water bath with gentle agitation. Blots
were then washed 3 times for 5 min each with TBST before re-blocking and subsequentChapter 2. Materials and Methods
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incubation with another primary antibody.
2.5.6 Antibodies
Antibody Mol Wt Dilution Species Source
GSK3b--pSer9 46 kDa 1:1000 Rabbit Sigma
EGFR(1005) 175 kDa 1:1000 Rabbit Santa Cruz
Phospho-EGFR
(Y1086)
175 kDa 1:1000 Rabbit Zymed
acetylated-tubulin 55 kDa 1:1000 Mouse Sigma
HECD1 135 kDa 1:1000 Mouse CRUK
Flag (M1) Relevant to
the fusion
protein
1:1000 Mouse Sigma
Phospho-ERK1/2 44, 42 kDa 1:4000 Rabbit Cell signalling
ERK 1/2 44, 42 kDa 1:1000 Goat Santa Cruz
Phosphor-Akt
(Ser 473)
60 kDa 1:1000 Mouse Cell signalling
b-actin 42 kDa 1:10000 Mouse SigmaChapter 2. Materials and Methods
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2.6 Immunoprecipitation
When cultured cells reached a certain level of confluence (50% or 90%), lysates for
immunoprecipitation were prepared by scrapping cells into ice-cold NP40 buffer (20 mM
Tris HCl pH 8, 137 mM NaCl, 10% glycerol, 1% Nonidet P-40 (NP-40), 2 mM EDTA,
supplemented by complete protease inhibitor) 0.5ml/T75, then on an agitator for 30
minutes at 4
oC, and followed by centrifugation at 12000rpm, 20 minutes at 4
oC. The
supernatant was aspirated and placed in a fresh tube on ice, followed with BCA assay.
Equal amount of protein samples were cultured with either EGFR (Rabbit, Santa Cruz,
SC-03. 1mg/300mg total protein), or HECD1 (Mouse, CRUK, 0.6mg/ml. 1ml/200mg
total protein), or relevant isotype antibodies, over night on agitation at 4
0C. Each sample
then was baited with 30ml protein A (for rabbit IgG) or G (for mouse IgG) (made into
100ml beads slurry with PBS for each IP reaction), followed by agitation for 4h, at 4
0C.
Lysate-beads mixture was then centrifuged to precipitate targeted protein and remove
supernatant. After three times wash in lysis buffer, 20ml of 5x lamemli buffer was added
to each sample, and then boiled at 100
0C for 5 minutes. Samples were stored at –20
0C,
ready for western blot. For longer storage, stored at –80
0C.
2.7In Situ Hybridisation assay
In situ probes were generated from Lrig1 cDNAas described previously (Suzuki, Miura et
al. 2002). Hybridisation with a -actin antisense probe served as a positive control andChapter 2. Materials and Methods
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was performed as described previously (Suzuki, Miura et al. 2002). This assay was
performed by Richard Poulsom at the CRUK London Research Institute.
2.8 Real-time RT-PCR analysis
In order to minimise degradation of RNA, all reagents were made with molecular biology
grade DEPC-treated deionised water (Ambion, TX, USA). All equipment was cleaned
thoroughly using RNaseZap and nuclease free pipette tips (Continental Lab Products, CA,
US) were used for all procedures involving RNA.
2.8.1 RNAextraction
2.8.1.1 Preparation of lysates from adherent culture cells
RNA was isolated from MTECs, A549, H357 and BEAS-2b cells was isolated from
cultured or freshly isolated human and murine tracheal epithelial cells using a
commercially available SV RNAisolation kit (Promega).
Cells were detached in trypsin-EDTA solution, then were collected in a sterile centrifuge
tube by centrifugation at 500x g for 5 minutes, and the supernatant discarded. After
adding 175 ml of RNA Lysis Buffer to up to 1x10
6 cells (Passing through a 20 – gauge
needle would be required for 1x10
6~5x10
6 cells in order to shear the genomic DNA).
Lysates were stored at -80
oC before use.Chapter 2. Materials and Methods
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2.8.1.2 Preparation of lysates from tissue samples
For real time qRTPCR, tracheas were removed and immediately snap frozen in liquid
nitrogen. Each sample was then pulverised into a fine powder under liquid nitrogen and
then immediately transferred to the tube containing 175ml of RNA Lysis Buffer. Lysates
were stored at -80°C before use.
2.8.1.3 RNApurification by centrifugation
350ml of RNA Dilution Buffer was applied to the lysates. The lysates were mixed and
then placed in a heating block at 70
oC for 3 minutes, followed by centrifugation at
12,000-14,000 x g for 10 minutes at room temperature. The cleared lysates were
transferred to a fresh microcentrifuge tube by pipetting, then 200ml 95% ethanol added
and mixed. The mixture was transferred to the spin column assembly before
centrifugation at 12,000-14,000 x g for one minute. The liquid in the collection tube was
discarded, and 600ml of RNA Wash Solution was applied to the spin column assembly
before another centrifugation at 12,000-14,000 x g for one minute. 50ml of freshly
prepared DNase incubation mix combing 40ml yellow core buffer, 5ml 0.09M MnCl2 and
5 ml of DNase I enzyme was applied to each sample in the collection tube. After gentle
pipetting, the mixture was incubated for 15 minutes at room temperature. 200ml of DNase
Stop Solution was added, followed by centrifugation at 12,000-14,000 x g for one minute.
The samples were then washed twice in RNA Wash Solution before centrifugation at high
speed. 100ml nuclease-free water was added to each sample and the elution containing
purified RNA was collected in the elution tube by centrifugation. RNA samples wereChapter 2. Materials and Methods
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stored at -80
oC.
2.8.1.4 RNAIsolation from human biopsies and LASER capture microdissection
RNA from carcinoma in situ (CIS) lesions and a normal area of epithelium was LASER
micro-dissected from formalin fixed, paraffin embedded (FFPE) tissues from 10 patients.
Briefly, multiple sections of each sample were cut, with the first and last in a series
stained with H&E for inspection by two lung pathologists. After confirming the diagnosis,
the samples were LASER capture microdissected using the Zeiss Palm Microbeam system
(Carl Zeiss). RNA was extracted from both microdissected CIS and normal lung
epithelium FFPE tissues using the RNeasy FFPE kit (Qiagen). This experiment was
performed by Dr Vitor Hugo Teixeira.
Total RNA was DNase-treated to remove contaminating genomic DNA using an Ambion
DNA-free kit. This kit uses DNase I to nonspecifically cleave genomic DNA into 5’
phosphorylated oligonucleotides.    The 17μl isolated total RNA was added to 2μl DNase 
buffer, and 1μl DNase I reagent, vortexed, and incubated for 20 minutes at 37°C.    The 
reaction mixtures were placed on ice, and 2μl inactivation resin, which binds DNase I, 
was then added. The tubes were vortexed and incubated at room temperature for 1 minute,
before centrifugation at 2300g for 2.5 minutes at 4°C to pellet the inactivation resin. The
supernatant containing the RNAwas removed to fresh tubes without disturbing the DNase
inactivation resin, which was then discarded.
The quantity of RNA was assessed using the Ultrospec 3000 spectrophotometer by
measuring the A260, as described previously with DNA quantification. The yield of RNAChapter 2. Materials and Methods
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(µg/ml) was calculated by A260 x 40 x dilution factor, which is based on the assumption
that A260 = 1 for a 40µg/ml solution. The quality of the RNA was then assessed by
running samples on an agarose gel. Samples were prepared as 1μl total RNA dissolved in 
11μl  DEPC-treated  water,  with  3μl  loading  buffer  (48%  (v/v)  deionoised  formamide 
(Invitrogen), 6% (v/v) formaldehyde (BDH), 5% (v/v) glycerol, 0.1% (v/v) ethidium
bromide 20 mM MOPS, 5 mM sodium acetate and 1 mM EDTA pH 8.0 made up in
DEPC-treated water and dyed with bromophenol blue). Each RNA sample was heated to
65°C for 5 minutes and placed on ice prior to loading. The RNA was separated through a
1.5% agarose-formaldehyde gel (6% (v/v) formaldehyde, 1.5% (w/v) agarose, 20mM
MOPS, 5mM sodium acetate, 1mM EDTA, pH 8.0, made using DEPC–treated water) at
80mV for 45 minutes. RNA images were then visualised using a UV transilluminator as
with the DNA previously. A ratio of approximately 2:1 of the intensities of the 28S
rRNA to the 18S rRNA bands was taken as confirmation that the RNA was not
significantly degraded.
2.8.2 cDNAsynthesis
Complementary DNA (cDNA) was prepared by reverse transcription using qScript
TM
cDNA Supermix kit from Quanta Biosciences. 100ng ~1μg total RNA of each sample was 
added to a reaction mix of 4 ml 5x qScript Cdna supermix (containing optimized
concentrations of MgCl2, dNTPs, recombinant RNase inhibitor protein, qScript reverse
transcriptase, random primers, oligo (dT) primer and stabilizers), RNase/DNase-free
water,  in  a  20μl  reaction  volume.  The  mix  was  incubated  at  room  temperature  for  5 
minutes, 42°C for 30 minutes, 85°C for 5 minutes, and then 4°C for 5 minutes, using aChapter 2. Materials and Methods
84
pre-programmed tetrad thermocycler.
Quantitative PCR was performed under standard conditions using an Eppendorf real-time
PCR machine. All samples were run as triplicates with a minimum of two samples /
treatment type. Quantification was based on Ct calculations, and all samples were
compared against 2-microglobulin and 18S as controls. Taqman pre-designed
inventoried probes and 2x PCR Master mix were used for all analyses (Applied
Biosystems).
2.8.3 Real-time RT-PCR
Taqman pre-designed, recommended, inventoried probes and 2x PCR Master mix were
used for all analyses (Applied Biosystems). All samples were run as triplicates with a
minimum of two samples / treatment type. Quantitation was based on Ct calculations,
and all samples were compared against 2-microglobulin and 18S. cDNA (1μl) was added 
to 19 ml of reaction system containing10μl of a 2x mastermix, 1ml of 20x probe, and 8ml 
of nuclease-free water, and placed in a qPCR white plate (ABgene). Each plate was
centrifuged for 2 minutes at 2000rpm at 4°C, placed in the LightCycler carousel, and run
under the standard Applied Biosystems cycling conditions: one cycle of 50 °C for two
minutes, and then 95 °C for 10 minutes followed by forty cycles of 95 °C for 15 seconds,
60 °C for one minute.Chapter 2. Materials and Methods
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Probe Gene name Amplicon length
Hs00394267_m1 LRIG1 96
Hs01006148_m1 LRIG1 58
Hs01076090_m1 EGFR 57
Hs 01076092_m1 EGFR 103
Hs 00170423_m1 CDH1 117
Hs00187842_m1 b2M 64
Hs03928985_g1 18S 90
Mm00456116_m1 Lrig1 82
Mm01247357_m1 Cdh1 71
Mm00433023_m1 egfr 85
Mm00437762_m1 b2m 77
Mm03928990_g1 18s 61
Mm00441533_g1 snail homolog 1 79
Mm00441531_m1 snail homolog 2 (slug) 98
Mm00442036_m1 Twist homolog 1 113
Mm00432359_m1 Cyclin D1 58
2.9 Statistical analysis
Two tailed unpaired t-tests were performed to assess the significance of differences
between epithelial heights and signal intensity between 2 groups and the non-parametric
Mann Whitney U test was used for cell phenotype and proliferation. One way ANOVAChapter 2. Materials and Methods
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and Turkeys Multiple Comparison test was performed to assess signal intensity from
fluorescent images between three groups. Statistical significance was accepted at p<0.05
for all analyses, and error bars represent standard error of the mean. All statistical analyses
were performed using GraphPad Prism and Microsoft Excel.Chapter 3. Results-LRIG1
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CHAPTER 3．RESULTS I – LRIG1
3.1 Lrig1 expression in the murine upper airways
In situ hybridisation staining shows Lrig1 present in WT murine Embryonic airways
(E14.5) (Figure 3.1a) and in adult murine airways throughout the trachea and first few
bronchial divisions (Figure 3.1b).Chapter 3. Results-LRIG1
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a
b
Figure 3.1 Lrig1 expression in the upper airways of mice.
In situ hybridisation staining shows Lrig1 present in WT murine Embryonic airways (E14.5) (a) and
in adult murine airways throughout the trachea and first few bronchial divisions (b). Original
magnification: ax5; bx20Chapter 3. Results-LRIG1
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3.2 Phenotype of Lrig1-defective mice
3.2.1 Deletion of Lrig1 causes hyperproliferation of the upper airways
To delineate the in vivo function of Lrig1 in the airways I examined Lrig1 depleted mice
(Lrig1-/-) (Suzuki et al). The trachea and first two bronchial generations demonstrated
hyperplasia (Figure 3.2a) resulting in a significant increase in airway epithelial thickness
compared to litter mate controls (meanSEM; 24.9m ±1.2 vs 19.1m ±1.7; unpaired T
test p<0.05). Ki67 staining of the trachea and bronchi confirmed hyperproliferation of
Lrig1-/- mice airway epithelium with 8.6%  1.1 vs 2.4%  0.3 of cells staining positively
for Ki67 (Mann Whitney; p<0.05) (Figure 3.2b-c).Chapter 3. Results-LRIG1
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Figure 3.2 Deletion of Lrig1 causes hyperproliferation of the upper airways.
(a-d) compares Lrig1-/- mice and litter mate controls. (a,c) H&E staining with quantification of
tracheal epithelial thickness (unpaired t test, mean±SEM, 24.9m ±1.2 vs 19.1m ±1.7; p<0.05).
(b,d) Ki67 immunostaining and corresponding quantification (Mann Whitney test, 8.6% ±1.1 vs
2.4% ±0.3, p<0.05). Percentage of positive cells=antigen expressing cells over total nuclei. Scale
bars: 20m. n=4Chapter 3. Results-LRIG1
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3.2.2 Lrig1 depletion was confirmed by immunofluorescence and
qPCR
Lrig1 depletion in the Lrig1-/- mouse upper airway was confirmed by immuofluorescence
staining and qrtPCR of harvested mouse tracheal epithelial cells compared to control
animals (Figure 3.3).
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Figure 3.3 Confirmation of Lrig1 depletion in the Lrig1
-/-mouse upper airway.
(a-c) compares Lrig1-/- mice and litter mate controls. Immunostaining (a,b) and qrt-PCR
quantification (c) for Lrig1. Scale bars: 20mChapter 3. Results-LRIG1
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3.2.3 Lrig1 depletion does not effect airway epithelial cell
differentiation
The cellular make up of the Lrig1 depleted mouse airway was normal with equivalent
percentages of basal, Clara and ciliated cells (Figure 3.4).Chapter 3. Results-LRIG1
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Figure 3.4 Cell type distribution of Lrig1 depleted mouse airway.
Immunostaining and percentage antigen expressing cells of total cells, of keratin 14 (K14, basal
cell marker), Clara cell specific protein (CCSP, Clara cell marker) and acetylated tubulin (ACT,
ciliated cell marker). Scale bars 20µm.Chapter 3. Results-LRIG1
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3.3 Lrig1 is downregulated in normal upper airway repair
On damage of the murine airways with polidocanol (a detergent agent that removes the
surface airway epithelium leaving an intact basement membrane) I saw that that after 48
hours (at the time of peak proliferation in the regeneration of the airways, Figure 3.5)
there was a fall in Lrig1 expression as determined by immunofluorescence, in situ
hybridisation while at day 7 when the regenerated epithelium begins differentiating
(Figure 3.5) I saw a return of Lrig1 expression to baseline homeostatic levels (Figure 3.6).Chapter 3. Results-LRIG1
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Figure 3.5 Demonstration of polidocanil damage on the upper airway.
Panels show airway epithelium at days 0 (a, d and g), day 2 (b, e and h) and day 7 (c, f and i) after
damage stained with K14 (a, b and c), BrdU (d,e and f) and ACT (g, h and i). Original magnification:
x20Chapter 3. Results-LRIG1
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Figure 3.6 Lrig1 is downregulated in upper airway repair.
(a) in situ hybridisation and (b) immunofluorescence with histogram of signal intensity for Lrig1 (c)
in normal murine tracheal epithelium, before polidocanol-generated tracheal injury (day 0), day 2
and day 7 after injury (one way ANOVA and Turkeys multiple comparision test * day 0 vs day 2
p<0.01;  day 2 vs day7 p<0.05). Scale bars: 20mChapter 3. Results-LRIG1
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3.4 Lrig1 depletion leads to increased EGFR phosphorylation
In the epidermis Lrig1 is known to regulate EGFR signalling leading to a reduction in
phosphorylated EGFR (Jensen and Watt 2006). I similarly confirmed using
immunofluorescent staining in normal homeostasis that Lrig1 depleted mice had
increased abundance of phospho-EGFR (Figure 3.7, day 0).
Two days post airway damage, levels increased in control animals in line with cellular
proliferation and were equivalent to Lrig1 depleted animals. However, by day 7 levels had
returned to baseline in control animals but remained elevated in the Lrig1
-/- mice (Figure
3.7, day 2 and 7).Chapter 3. Results-LRIG1
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Figure 3.7 Lrig1 downregulation in murine upper airway leads to upregulated
EGFR activation. Immunostaining with histogram of signal intensity of phospho-EGFR in
Lrig1-/- mice (KO) and litter mate tracheal epithelium before polidocanol-generated tracheal injury
day 0 (* unpaired T test p<0.05), and day 2 (p=0.8) and day 7 (* p<0.05) after injury. Scale bars
20µmChapter 3. Results-LRIG1
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3.5 Lrig1
-/- mice show increased cell proliferation
3.5.1 In vivo
This is associated with increased proliferation in Lrig1
-/- mice compared to litter mate
controls (32.7% ±5.1 vs 21.1% ±4.1, Mann Whitney p=0.03) (Figure 3.8). The dynamic
expression pattern of Lrig1 during injury suggests that it either controls airway cell
differentiation or proliferation. As Lrig1
-/- mice display normal epithelial differentiation,
this indicates that Lrig1 controls proliferation. We next investigated whether Lrig1 had a
role in density dependent growth inhibition.Chapter 3. Results-LRIG1
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Figure 3.8 immunostaining of Ki67 in Lrig1-/- and litter mate control tracheal
epithelium. immunostaining of Ki67 in Lrig1-/- and litter mate control tracheal epithelium , and
corresponding quantification (** Mann Whitney test, p<0.01). Scale bars 20µmChapter 3. Results-LRIG1
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3.5.2 Lrig1 depletion leads to a failure of cell-cell contact inhibition in
vitro
To further examine the hyperproliferative phenotype of the Lrig1
-/-mouse airway I used
murine tracheal epithelial cell (MTEC) air liquid interface (ALI) cultures. In ALI cultures
the initial proliferative phase of the culture is carried out submerged in media until day 9
followed by a differentiation phase of confluent cells at an air liquid interface (Figure
3.9a). Proliferation in sub-confluent MTEC cultures was examined at day 7 with the
addition of BrdU three hours before harvest. Alternatively MTEC cultures were taken to
an ALI at day 9 and then proliferation measured in confluent cultures at day 14 (Figure
3.9a).
Day 7 pre-confluent cultures showed high but equivalent cellular proliferation in Lrig1
-/-
and control MTECs (Figure 3.9b) however proliferation of Lrig1
-/- MTECs
post-confluence was significantly increased compared to litter mate controls (Figure 3.10).
Cell fate decisions of confluent Lrig1
-/-cultures were again normal with equivalent levels
of K14 and acetylated tubulin expressing cells (Figure 3.10).Chapter 3. Results-LRIG1
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Figure 3.9 Lrig1
-/- (KO) tracheal epithelial cells show similar proliferation at
cell pre-confluence in ALI culture.
(a) diagram of ALI culture and experimental time points. (b) immunostaining of BrdU in MTEC
culture pre-confluence and corresponding quantification (KO vs control, 55.9% ±9.5 vs 62.0%
±11.8, p>0.05, n=4). All statistical values, mean ±SEM, Mann Whitney U test.Chapter 3. Results-LRIG1
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Figure 3.10 Lrig1
-/- (KO) tracheal epithelial cells show continued proliferation
at cell confluence in ALI culture.
Immunostaining of BrdU in MTEC cultures day 14 (5 days after cell confluence) showed increased
BrdU immunostaining cells in Lrig1-/- MTECs compared to controls (9.7% ±3.4 vs 0.5% ±0.1,
p<0.05, n=4). Co-staining of keratin14 (K14) or acetylated tubulin (ACT) with BrdU, showing no
difference between KO and control MTEC differentiation at ALI culture day 14 (47.0% ±11.4,
54.2% ±9.2, respectively, p>0.05). All statistical values, mean ±SEM, Mann Whitney U test.Chapter 3. Results-LRIG1
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3.5.3 Lrig1-/- activated EGFR/ MAPK /ERK signalling pathway in
MTEC culture
Immuno-blots of Lrig1
-/- compared to control MTEC cultures demonstrated an increase in
phospho-EGFR and phospho-ERK1/2 under conditions with and without the EGF ligand
(Figure 3.11) confirming a downstream effect of Lrig1 expression on EGFR signalling.Chapter 3. Results-LRIG1
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Figure 3.11 Increased ERK1/2 phosphorylation of KO MTEC compared to
controls.
MTECs from control or KO mice were growth factor starved for 14h and stimulated or not for 30min
with 20ng/ml EGF. Cell lysates were immunoblotted with the indicated antibodies.Chapter 3. Results-LRIG1
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3.6 Ectopic LRIG1 arrested cell proliferation in human cancer
cell lines
This failure of density dependent growth inhibition in the Lrig1
-/- airway epithelial cells
led us to next investigate whether Lrig1 plays a role as a tumour suppressor in lung cancer
cells.
Lung A549 (adenocarcinoma) and H357 (squamous) cancer cell lines show little or absent
expression of LRIG1 compared to normal human bronchial epithelial cells (BEAS-2b)
while having a high expression of EGFR (Figure 3.12). These cells were transduced with
a retrovirus expressing a flag-tagged LRIG1 construct or empty vector control.
Immunofluorescence, immuno-blotting and qPCR confirmed transduction (Figure
3.13-14). I then performed experiments examining cell proliferation in pre-confluent and
confluent conditions.
3.6.1 Endogenous LRIG1 and EGFR expression in human cell lines
Lung A549 (adenocarcinoma) and H357 (squamous) cancer cell lines show little or absent
expression of LRIG1 compared to normal human bronchial epithelial cells (BEAS-2b)
while having a high expression of EGFR.Chapter 3. Results-LRIG1
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Figure 3.12 qPCR of endogenous LRIG1 and EGFR transcripts.
Shows loss of LRIG1 in cancer cells compared to control human airway cells.Chapter 3. Results-LRIG1
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3.6.2 The success of LRIG1 transduction
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Figure 3.13 Ectopic LRIG1 expression in A549.
Immunostaining of LRIG1 in A549-empty vector (EV) and A549-LRIG1flag transduced cells (a)
with LRIG1 qPCR and immunoblotting of flag-tagged LRIG1 (b) confirming expression. Original
magnification x40Chapter 3. Results-LRIG1
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Figure 3.14 Ectopic LRIG1 expression in H357
Immunostaining of LRIG1 in H357-empty vector (EV) and H357-LRIG1flag transduced cells (a)
with LRIG1 qPCR and immunoblotting of flag-tagged LRIG1 (b) confirming expression. Original
magnification x40Chapter 3. Results-LRIG1
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3.6.3 LRIG1 transduction reduces post confluence cancer cell
proliferation
Pre-confluent LRIG1 expressing A549 and H357 cells showed no change in proliferation
rate compared to empty vector control cells (A549; 78.2% ±3.8 vs 74.9% ±4.4, p>0.05:
H357; 58.0% ±6.6 vs 56.1% ±3.9%, p>0.05) (Figure 3.15a and 16a). However at
confluence, LRIG1 transduced A549 and H357 cells demonstrated a significantly reduced
proliferative rate (A549s: 13.3% ±0.7, 6.1% ±1.7, p<0.05: H357; 56.3% ±7.7 vs 40.1%
±6.9, p<0.05) (Figure 3.15b and 16b).Chapter 3. Results-LRIG1
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Figure 3.15 A549 immunostaining of BrdU in EV and LRIG1 transduced cells.
A549 immunostaining of BrdU in EV and LRIG1 transduced cells at pre (a) and post confluence (b),
with corresponding histogram of BrdU positive cells. Original magnification x10. (Mann Whitney *
p<0.05)Chapter 3. Results-LRIG1
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Figure 3.16 H357 immunostaining of BrdU in EV and LRIG1 transduced cells.
H357 immunostaining of BrdU in EV and LRIG1 transduced cells at pre (a) and post confluence (b),
with corresponding histogram of BrdU positive cells. Original magnification x10. (Mann Whitney *
p<0.05)Chapter 3. Results-LRIG1
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3.6.4 LRIG1 transduction of A549 and H357 cancer cells reduces
colony formation efficiency (CFE)
LRIG1 transduced A549 and H357 cells also demonstrated a reduction in the number
(A549-EV 28.7% ±3.4 vs A549-LRIG1 16.2 ±2.9, p<0.05; H357-EV 14.3 ±2.2 vs
H357-LRIG1 7.5 ±1.2, p<0.05) and size of colonies (A549-EV 16.2% ±2.1 vs
A549-LRIG1 4.8 ±1.0, p<0.05; H357-EV 2.6% ±0.5 vs H357-LRIG1 1.0 ±0.2, p<0.05) in
colony forming assays (Figure 3.17 and 18).Chapter 3. Results-LRIG1
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Figure 3.17 CFE of A549 transduced cells.
A549 cells showing LRIG1 transduction reduced size and number of colonies (Mann Whitney *
p<0.05; ** p<0.01)Chapter 3. Results-LRIG1
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Figure 3.18 CFE of H357 transduced cells.
H357 cells showing LRIG1 transduction reduced size and number of colonies (Mann Whitney *
p<0.05)Chapter 3. Results-LRIG1
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3.6.5 LRIG1 transduction of BEAS2b cells expressing endogenous
LRIG1 does not affect proliferation or CFE
Of note normal bronchial epithelial cells (BEAS2b cells) that have endogenous expression
(see Figure 3.12) of LRIG1 show no change in cell proliferation or colony forming
efficiency with the introduction of additional synthetic LRIG1 (Figure 3.19-20).Chapter 3. Results-LRIG1
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Figure 3.19 LRIG1 transduction causes no change in BEAS-2b proliferation.
Immunostaining of flag in BEAS2b-empty vector (EV) and BEAS2b-LRIG1flag transduced cells
(a,b) ; and BrdU in EV and LRIG1 transduced cells at post confluence (c,d). Original magnification
(a, b) x40; (c, d) x10Chapter 3. Results-LRIG1
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Figure 3.20 CFE of BEAS-2b EV and LRIG1-transduced cells.
CFE of BEAS-2b EV and LRIG1-transduced cells showing no difference in CFE (Total Number of
colonies BEAS2b-EV 24.2% ±0.9vs BEAS2B-LRIG1 27.6 ±3.5, p=0.88; and large colonies
BEAS2b-EV 13.7% ±1.1vs BEAS2B-LRIG1 12.4 ±1.2, p=0.70)Chapter 3. Results-LRIG1
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3.7 LRIG1 complexes with E-cadherin at the adherens junction.
3.7.1 Activity of EGFR signalling and E-cadherin expression in LRIG1
transducedA549
To understand how LRIG1 leads to reduced proliferation on cell-cell contact I first
examined the activation of the EGFR signalling pathways in LRIG1 depleted cells
compared to LRIG1 transduced cells. Using immunoblotting I found the introduction of
LRIG1 to cancer cells reduced phospho-EGFR levels and the downstream effecter
phospho-ERK1/2, while having no effect on the activation Akt measured by
immunoblotting phospho-Akt (Figure 3.21a).
I hypothesised that LRIG1 was causing its effect at the adherens junction. Using
immunoblotting and qPCR we found LRIG1 transduction did not significantly alter
E-cadherin protein and mRNA levels (Figure 3.21b and 21c) within A549 cancer cells
(Figure 3.21c).Chapter 3. Results-LRIG1
120
Flag
b-actin
EGFR
pEGFR
ERK2
pERK1/2
pAKT
EV LRIG1 A549
EV LRIG1 A549
E-cadherin
b-actin
A549-EV A549-LRIG1
0
50
100
150
200
C
D
H
1
m
R
N
A
%
o
f
E
V
a b
c
Figure 3.21 Immunoblots of A549-EV and A549-LRIG1 cells.
(a) immunoblots of A549-EV and A549-LRIG1 cells with the indicated antibodies. (b) qrt-PCR of
E-cadherin (CHD1), in A549-EV and A549-LRIG1. (c) immunoblot of A549-EV and A549-LRIG1
cells for E-cadherin.Chapter 3. Results-LRIG1
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3.7.2 LRIG1 colocaiises at cell-cell junctions with EGFR and
E-cadherin
EGFR and E-cadherin have been previously shown to co-localise at cell-cell contacts. I
confirmed this in A549 cells using confocal microscopy and further showed
co-localisation of Lrig1 with EGFR (Figure 3.22a and 22b). This association EGFR and
LRIG1 at the cell membrane was blocked with the addition of EDTA for 2 hours (Tobey,
Argote et al. 2004) to cultures to disrupt the adherens junction suggesting the complex is
formed there with E-cadherin (Figure 3.22c).Chapter 3. Results-LRIG1
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Figure 3.22 Confocal image of E-cadherin, LRIG1 and EGFR immunostaining
in A549-LRIG1 cells.Chapter 3. Results-LRIG1
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3.7.3 LRIG1 co-immunoprecipitates with EGFR and E-cadherin
To confirm this association I next performed immunoprecipitation experiments showing
that E-cadherin could be co-precipitated with EGFR at low levels in the absence of
LRIG1, however after LRIG1 transduction this co-immunoprecipitation is greatly
increased (Figure 3.23a and 23b). LRIG1 was also co-immunopreciptated with both
EGFR and E-Cadherin suggesting the three molecules form a complex at cell confluence.
This was shown using both EGFR and E-cadherin as the immunoprecipitation bait (Figure
3.23b). Further, EGFR and E-cadherin complex formation is reduced in the absence of
LRIG1. Therefore in both tracheal epithelial cells and lung cancer cells it appears LRIG1
is required for effective density dependent growth inhibition through inhibition of the
EGFR-ERK1/2 pathway and produces this effect after forming a complex at the cell
membrane with E-cadherin and EGFR at cell-cell contact.Chapter 3. Results-LRIG1
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Figure 3.23 Immunoprecipitation of A549 transduced cells.
Immunoprecipitation experiments of cell lysates from A549-EV and A549-LRIG1 with an EGFR
antibody (a) and an E-cadherin antibody (b) with subsequent immunoblots with the indicated
antibodies.Chapter 3. Results-LRIG1
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3.8 Reduced LRIG1 expression occurs in pre-invasive lung
cancer lesions
Several studies have shown loss of LRIG1 occurs in cancer and is associated with a poor
prognosis (Tanemura, Nagasawa et al. 2005; Guo, Nilsson et al. 2006; Jensen, Jones et al.
2008; Lindstrom, Ekman et al. 2008). In the above experiments I show that loss of Lrig1
is associated with hyperproliferation in vivo and loss of density dependent growth
inhibition in vitro. I therefore hypothesised that LRIG1 loss is an early initiation step for
the development of cancers in the airways with the resultant high proliferative background
allowing an increased accumulation of genetic abnormalities.
I therefore studied 10 pre-invasive lung cancer lesions and compared them to normal
airway epithelial biopsies from the same patients.
Immunohistochemistry showed reduced immunoreactivity of LRIG1 in pre-invasive
tissue compared to normal epithelium in all 10 patients, which was confirmed in 9 with a
significant reduction in gene expression as measured by qPCR (one sample failed RNA
extraction) (Figure 3.24a and b). This reduction in LRIG1 expression was mirrored by an
increase in phospho-EGFR immunoreactivity and gene expression in the pre-invasive
lesions compared to normal control epithelium (Figure 3.24c, d). This data confirms loss
of LRIG1 expression is an early event in the pathogenesis of squamous cell lung cancer.Chapter 3. Results-LRIG1
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Figure 3.24 Early loss of LRIG1 in pre-invasive lung cancer lesions.
(a) representative LRIG1 immunostained section of human lung carcinoma-in-situ (CIS) and
normal epithelium samples showing the downregulation of LRIG1 in CIS samples. (b) qrt-PCR
analysis of relative mRNA expression of LRIG1 in CIS and normal lung epithelium samples. There
was 2 fold change of LRIG1 mRNA level between CIS (n=10) and patient matched normal (n=10)
samples. (c) Representative EGFR immunostaining human lung CIS and normal epithelial sample
showing EGFR upregulation in CIS samples. (d) qPCR analysis of relative mRNA expression for
EGFR in CIS and normal lung epithelium samples. There was 2.4 fold change difference between
CIS (n=10) and normal (n=10) samples. Error bars represent the standard error of the mean;
*p<0.05. Original magnification (a)x20, (c)x40Chapter 4. Results--Catenin
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CHAPTER 4. RESULTSII- -CATENIN
4.1 catenin expression in normal or repairing murine trachea
4.1.1 Basal stem cells activate catenin during wound repair
To assess whether catenin is active in normal or repairing airways I used TOPgal
catenin reporter mice (Li, Li et al. 2009). Mice were untreated or given 2% polidocanol
by oropharyngeal instillation to damage their tracheas. Normal and polidocanol damaged
tracheas recovered for 7 days were stained with X-gal to detect galactosidase reporter
gene activity (Li, Li et al. 2009). Only sporadic clusters of -catenin signalling cells were
present in two of four uninjured tracheas (blue stained cells, Figure 4.1A, B). After
damage all tracheal samples exhibited robust reporter gene activity throughout their
epithelium (Figure 4.1C, D). X-gal staining was never detected in transgene negative
(wild type) controls (data not shown). These results demonstrate that tracheal catenin
activation is predominantly associated with epithelial repair.Chapter 4. Results--Catenin
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Figure 4.1 Tracheal repair is associated with stem cell catenin activation.
(A-D) Whole mounts of normal (A, B) and polidocanol damaged (C, D) TOPgal tracheas stained
with X-gal to detect -catenin (blue). Dashed boxes (A, C) indicate areas magnified in (B, D). The
tracheal proximal-distal (P->D) axis is indicated (A, C) and scale bars represent 100m (A-D). Cells
isolated from tracheas were labelled using DAPI, CD45, EpCam, GSI-4 lectin, and FDG (Figure
26), and FDG-reactive, nonhematopoietic EpCam (+)/lectin (-) nonbasal (black, E, F) and EpCam
(+)/lectin (+) basal (red, E, F) epithelial stem cell abundance was determined for control and
polidocanol damaged samples. The tracheal proximal-distal (P->D) axis is indicated (A, C) and
scale bars represent 100m (A-D).Chapter 4. Results--Catenin
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4.1.2 catenin signalling occurs predominately within activated basal
stem cells.
To determine the abundance and phenotype of catenin signalling cells I used FDG,
EpCam and GSI- lectin antibody staining and flow cytometry (to detect TOPgal
signalling, epithelial, and basal stem cells, respectively (Figure 4.2). Nontransgenic mice
and single stain controls were used to set all gates. In the absence of injury only rare
EpCam (+)/GSI- lectin (+) basal stem cells exhibited FDG staining resulting from
TOPgal activity (red bar, Figure 4.1E). In contrast, FDG staining was present in 20-60%
of EpCam(+)/lectin(+) basal stem cells and 5-20% of non-basal EpCam(+)/lectin(-) cells 7
days after damage (Figure 4.1F). This indicates that catenin signalling occurs
predominately within activated basal stem cells.Chapter 4. Results--Catenin
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Figure 4.2 Flow cytometry plots of TOPgal tracheal epithelial cell
preparations. Control (A-C) and polidocanol damaged, 7-day recovered (D-F) tracheal
epithelial cells were selected on the basis of forward scatter (box, A, D), CD45 and DAPI negativity
(box, B, E). (C, F) Basal and non-basal epithelial cells were further distinguished based on
GSI-lectin and EpCam reactivity (red and black boxes, respectively).Chapter 4. Results--Catenin
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4.2 Basal stem cell catenin determines tracheal growth and
differentiation
To assess the role of catenin in basal stem cell growth TOPgal reporter mice were
crossed with a K14-dependent, oestrogen responsive and N-terminally truncated -catenin
transgenic line (∆N--cateninER, termed D4) (Silva-Vargas, Lo Celso et al. 2005). These
TOPgal x D4 (TOP-D4) bitransgenic mice activate catenin only in K14-expressing
basal stem cells upon tamoxifen exposure. I treated TOP-D4 mice with 5 mg tamoxifen on
days 0, 2, 4, 7, and 9 and culled mice on day 10.
Figure 4.3 Tamoxifen dosimetry schedule.Chapter 4. Results--Catenin
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FDG flow cytometry was used to compare the abundance, specificity and phenotype of
catenin signalling cells (Figure 4.4A, B). I observed increased catenin signalling
specifically within tracheal stem cells only after tamoxifen treatment.
H+E staining revealed that the tracheal height and cellular density of tamoxifen treated
TOP-D4 mice was increased relative to controls (Figure 4.5A, B, G). Immunostaining
revealed that TOP-D4 tracheas contained significantly more basal stem cells and
increased CCSP-expressing cell differentiation (Figure 4.5C-F, H). There was
additionally a trend toward reduced ciliated cell abundance after tamoxifen treatment
(orange, Figure 4.5E, F, H) and significantly increased proliferation in tamoxifen treated
TOP-D4 tracheas relative to controls (Figure 4.5I). Thus, adult tracheal stem cell
catenin activity determines tracheal epithelial growth and differentiation.Chapter 4. Results--Catenin
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Figure 4.4 Basal stem cell catenin determines tracheal growth and
lineage choice. (A, B) Representative flow cytometry plot (A) and quantitation of FDG reactive
cell incidence (B) in TOP-D4 or TOPgal cells.Chapter 4. Results--Catenin
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Figure 4.5 Phenotype of TOP-D4 mice. (A, B) Representative H+E stained, tamoxifen
treated TOPgal (A) and TOP-D4 (B) trachea sections. (C-F) Representative tamoxifen treated
TOPgal (C, E) and TOP-D4 (D, F) sections stained with antibodies directed against K14 (green, C,
D), BrdU (red, C, D), CCSP (green, E, F) and acetylated tubulin (orange, E, F). (J-L) Quantitation of
epithelial height (J), cellular phenotype (K), and BrdU incidence (L) in TOPgal (black) and TOP-D4
(red) tracheas. Scale bars (D-I) are 100m; asterisks (C, J-L) represent statistical significance at
p<0.05 (*) or p<0.005 (**) as indicated.Chapter 4. Results--Catenin
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4.2 catenin signalling is dispensable for airway homeostasis
Separately I investigated whether stem cell catenin signalling was necessary for
tracheal homeostasis or repair using a K14-dominant negative (N-terminally truncated)
Lef1 transgenic mouse model (K14-dnLef1, (Niemann, Owens et al. 2002)). H+E
staining and indirect antibody immunofluorescence revealed no differences between
uninjured wildtype and K14-dnLef1 tracheal morphology, stem cell abundance, and
epithelial proliferation (Figure 4.6A-D, quantitation in Figure 4.6M, N). Additionally,
although it has been previously reported that Lef1 was required for tracheal submucosal
gland development (Duan, Sehgal et al. 1998; Duan, Yue et al. 1999), both K14-dnLef1
and wildtype tracheas exhibited comparable submucosal gland abundance, distribution,
and cellular phenotypes (Figure 4.7). This agreed with previous reports that catenin
signalling is dispensable for airway homeostasis (Zemke, Teisanu et al. 2009).
To assess whether tracheal repair was perturbed in the absence of catenin signalling I
compared polidocanol damaged wildtype and K14-dnLef1 transgenic tracheas. Three days
after damage the epithelial height and cell density of K14-dnLef1 transgenic tracheas was
reduced compared with wildtype (Figure 4.6E, F; quantitated in Figure 4.6M). Although
this difference was not dependent on reduced K14-dnLef1 basal cell abundance I did
observe significantly reduced cell proliferation in transgenic mice recovered for three
days (Figure 4.6G, H, N). Seven days after damage cell proliferation, epithelial height,
and cellular phenotype were all similar between wildtype and transgenic mice. Thus, stem
cell catenin signalling was necessary for tracheal repair but not required in normal
tracheal development or homeostasis (Niemann, Owens et al. 2002).Chapter 4. Results--Catenin
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Figure 4.6 Stem cell catenin inhibition delays normal epithelial repair.
(A-L) H+E staining (A, B, E, F, I, J) and indirect immunofluorescence (C, D, G, H, K, L) using
keratin 14 (green) plus BrdU (red) antibodies in uninjured (A-D) or polidocanol injured, 3 (E-H) and
7 day (I-L) recovered wildtype (A, E, I, C, G, K) and K14-dnLef1 transgenic tracheas (B, F, J, D, H,
L). (M) Quantitation of average epithelial height in uninjured control and polidocanol damaged
wildtype and K14-dnLef1 tracheas (black and red bars, respectively). (N) Quantitation of
BrdU-reactive cell incidence per 100m basement membrane length in control, 3-day and 7-day
recovered wildtype and transgenic tracheas (black and red bars). Scale bars (A-L) are 100m;
asterisks (M, N) denote significance at p<0.05.Chapter 4. Results--Catenin
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Figure 4.7 Submucosal gland development and homeostasis are unaffected
by catenin inhibition. (A, B) Representative H+E stained tissue sections of wildtype (A)
and K14-dnLef1 (B) tracheal submucosal glands. (C, D) Wildtype (C) and dnLef1 (D) submucosal
glands stained using antibodies directed against K14 (green) plus BrdU (red). Scale bars are
100m.Chapter 4. Results--Catenin
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4.4 Basal stem cell catenin activity promotes an EMT
phenotype
Previous studies have established that catenin may regulate epithelial fate via
modulation of EMT phenotypes (Heuberger and Birchmeier 2010). To determine
whether stem cell catenin activity induced an EMT within the trachea I examined
E-cadherin abundance and target gene expression. Tamoxifen treated TOP-D4 tracheas
exhibited significantly reduced E-cadherin levels throughout their epithelium relative to
controls (Figure 4.8A, B; control average pixel intensity 141.7±11.1 out of 256 versus
97.3±8.2 in TOP-D4). I isolated RNA from 5 control and 5 TOP-D4 tamoxifen-treated
tracheas and examined the expression of EMT-associated target genes Twist, Snail, Slug
and Cyclin D1. TOP-D4 samples exhibited increased expression of Cyclin D1, Twist,
and Snail (but not Slug) relative to controls (Figure 4.9C-F). Dual fluorescent
immunostaining confirmed that catenin increased Snail expression throughout the
trachea (red, Figure 4.9A, B). I also assessed epithelial smooth muscle actin (SMA) and
Muc5AC cell abundance to determine whether catenin induced a complete or partial
EMT and or metaplasia (Figure 4.10). I found that catenin activation increased
Muc5AC(+) goblet cell abundance but did not promote tracheal epithelial SMA
expression.Chapter 4. Results--Catenin
139
A B
K14 + E-cadherin
TOPgal 10 days
K14 + E-cadherin
TOP-D4 10 days
Figure 4.8 Tracheal stem cell -catenin signalling reduces E-cadherin levels.
(A, B) Representative tamoxifen treated TOPgal (A) and TOP-D4 (B) sections stained with K14
(green) and E-cadherin (red). Scale bars (A, B) are 100mChapter 4. Results--Catenin
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Figure 4.9 Tracheal stem cell -catenin signalling increases the expression
of EMT-associated target genes (A, B) Representative tamoxifen treated TOPgal (A)
and TOP-D4 (B) sections stained with K14 (green) and Snail (red). (C-F) Quantitative PCR
analysis of total RNA from TOPgal (control, black) and TOP-D4 (red) tracheal epithelial cells
following tamoxifen treatment. Cyclin D1 (C), Twist (D), Snail (E), and Slug (F) abundance was
assessed and normalised to 2-microglobulin using ∆CT calculations. Scale bars (A, B) are 100m;
asterisks (C-E) represent statistical significance at p<0.05 (*).Chapter 4. Results--Catenin
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Figure 4.10 Tracheal stem cell -catenin activation promotes a partial EMT
(A, B) Tamoxifen-treated TOPgal (G, I) and TOP-D4 tracheal sections were stained with antibodies
directed against smooth muscle actin (SMA, green), and Muc5AC (red). Scale bars (A, B) are
100m.Chapter 4. Results--Catenin
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4.5 E-cadherin inhibition phenocopies-catenin activation
To assess whether catenin regulated tracheal differentiation by modulating intercellular
adhesiveness I used an air-liquid interface (ALI) model (Figure 4.11) (You, Richer et al.
2002).
Figure 4.11 Diagram of ALI model and inhibitory drug dosimetry schedule
Murine ALI cultures were grown in the presence of the GSK inhibitory (catenin
activating) drug SB415286 or the E-cadherin inhibitory monoclonal antibody DECMA-1;
DMSO was used as a control (Coghlan, Culbert et al. 2000; Kobayashi, Ikesue et al.
2006). Protein analysis of cell lysates harvested at day 21 revealed that treatment with
either 10 or 30M S15286 increased GSK Serine 9 protein phosphorylation (Figure
4.12A). I also observed increased expression of the catenin target protein Cyclin D1
upon treatment with 30M S15286 (Figure 4.12B, C).
Interestingly, although S15286, DECMA-1, and DMSO treated cells appeared similarChapter 4. Results--Catenin
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while in submersion culture, only DMSO treated cells exhibited abundant acetylated
tubulin differentiation following the switch to ALI (red, Figure 4.13A-C). Western blots
of protein isolated from these cultures confirmed this result (Figure 4.12). Treatment
with S15286 and DECMA-1 also moderately increased K14-expressing cell abundance
(green, Figure 4.13A-C). Separately, I assessed cell proliferation following treatment
with SB415286 or DECMA-1 by examining BrdU nucleoside incorporation. I found
that both catenin activation and E-cadherin inhibition increased epithelial cell
proliferation relative to controls (Figure 4.13D-F). I also examined cell surface
E-cadherin (green, Figure 4.13G-I) and ZO-1 protein abundance (red, Figure 4.13G-I) in
ALI cultures treated with SB415286, DECMA-1, and DMSO. E-cadherin staining was
reduced while ZO-1 levels were maintained in confluent ALI cultures treated with
SB415286 or DECMA-1.
Chapter 4. Results--Catenin
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Figure 4.12 GSK inhibitor activates catenin pathway.
(A) Protein blot of DMSO, 10- and 30-M SB415286-treated ALI cultures using indicated
antibodies. (B, C) Wholemount cyclin D1 (red) and keratin 14 (green) staining of DMSO (B), 30M
SB415286 (C) differentiated ALI cultures.Chapter 4. Results--Catenin
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Figure 4.13 E-cadherin inhibition phenocopies catenin activation.
Wholemount antibody staining of DMSO (A, D, G), 30M SB415286 (B, E, H), and DECMA-1
treated (C, F, I) differentiated ALI cultures. Antibodies included Keratin 14 (green, A-F), ACT (red,
A-C), BrdU (red, D-F), ZO-1 (red, G-I ) and E-cadherin (green, G-I). DAPI (blue) was used as a
nuclear counterstain (A-I).Chapter 4. Results--Catenin
146

catenin signalling promotes a preinvasive SCC cellular
phenotype
Finally to confirm if catenin activation could promote cellular phenotypes in human
airway cells in vitro consistent with those seen in preinvasive human SCCs I treated
immortalised human bronchial epithelial cells (iHBECs) with S15286. iHBECs
express keratins 5 and 14, form tight intercellular adhesions, and exhibit multipotent
differentiation when cultured at an air-liquid interface (Borthwick, Shahbazian et al. 2001).
Flow cytometric analysis of SB415286-treated iHBECs revealed significantly reduced
G0/1 and increased G2/M phase cells relative to DMSO-treated controls (Figure 4.14).
This was accompanied by reduced cell-surface E-cadherin protein abundance (Figure
4.15A, B) and an increase in EMT-associated catenin target gene expression (Figure
4.14B, Figure 4.15C).Chapter 4. Results--Catenin
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Figure 4.14 -catenin determines human airway proliferation
(A) Representative flow cytometry plot and quantitation of human bronchial epithelial cell (iHBEC)
cell cycle following DMSO (black line) or 30M SB415286 treatment (red line). (B) Cyclin D1
quantitative PCR analysis of total RNA isolated from iHBECs treated for 24 hours with DMSO
(black) or 30M SB415286 (red). Transcript abundance was normalised to 18S and quantitated
using ∆CT calculations.    Asterisks (A, B) represent significance of p<0.05 (*) or p<0.005 (**).Chapter 4. Results--Catenin
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Figure 4.15 -catenin determines human airway EMT phenotype
(A, B) E-cadherin antibody staining of iHBECs treated for 24 hours with DMSO (A) or 30M
SB415286 (B). (C) Quantitative PCR analysis of total RNA isolated from iHBECs treated for 24
hours with DMSO (black) or 30M SB415286 (red). Twist, Snail, and Slug transcript abundance
was normalised to 18S  and  quantitatedusing  ∆CT  calculations.    Asterisks  (C)  represent 
significance of p<0.05 (*) or p<0.005 (**).
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
catenin is associated with increased SCC severity
To first ascertain whether catenin was associated with SCC severity I examined
catenin localisation in 45 biopsy samples from patients with various stages of
preinvasive SCC (normal, metaplasia, mild, moderate, and severe dysplasia, carcinoma in
situ). Hematoxylin and eosin (H+E) staining revealed dramatic differences in tissue
morphology between each stage (compare metaplasia and severe dysplasia, Figure 4.16A,
B). All normal and metaplastic lung tissue sections stained for catenin exhibited
robust membrane associated catenin and no nuclear or cytoplasmic protein localisation
(Figure 4.16C). In contrast samples with mild to severe dysplasia and carcinoma in situ
exhibited extensive nuclear and cytoplasmic catenin abundance (Figure 4.16D, data
quantitated in Figure 4.16E).
Using Ki67 and E-cadherin immunostaining I determined cell proliferation was increased
in samples exhibiting nuclear or cytoplasmic catenin localisation relative to those with
membrane-associated -catenin (Figure 4.17A, B). Further, in severely dysplastic and
carcinoma in situ samples with nuclear or cytoplasmic catenin expression cell
proliferation was not restricted to the basal layer (arrow, Figure 4.17B). E-cadherin was
also reduced in basal cells with nuclear or cytoplasmic -catenin localisation (Figure
4.17C, D). Thus, increased airway catenin signalling is positively associated with
elevated proliferation and reduced E-cadherin abundance (Figure 4.17E, F).Chapter 4. Results--Catenin
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Figure 4.16 catenin activation is associated with increased preinvasive
SCC severity. (A-D) Representative images of metaplastic (A, C) and severely dysplastic (B, D)
SCC biopsies stained with H+E (A, B) or antibodies directed against -catenin (C, D). (E)
Quantitation of the percent of biopsy samples exhibiting membranous (white bars) or nuclear /
cytoplasmic -catenin (black bars). Scale bars (A-D) are 100m.Chapter 4. Results--Catenin
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Figure 4.17 catenin activation is associated with increased proliferation
and loss of E-cadherin in preinvasive SCC lesion (A-E) Representative images of
metaplastic (A, C) and severely dysplastic (B, D) SCC biopsies stained with antibodies directed
against Ki67 (A, B), and E-cadherin (C, D). (E, F) Overall Ki67 incidence and basal E-cadherin
abundance in samples with membranous or nuclear/cytoplasmic -catenin (white and black bars).
Scale bars (A-D) are 100m; asterisks (E) denote significance at p<0.005.Chapter 5. Discussion
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CHAPTER 5. DISCUSSION
I have examined two key signalling systems and their regulation of normal airway
homeostasis and importantly their role in the formation of early lung cancer lesions.
Understanding the mechanism of lung cancer development may lead to
chemopreventative strategies in the fight against this disease that currently presents late in
its course and has a very low cure rate.
The EGFR pathway
From my data in chapter 3 I identify LRIG1 as an important regulator of tissue
homeostasis in the major airways. I demonstrate that LRIG1 acts as a tumour suppressor
by forming a ternary complex at adhering junctions with E-cadherin and EGFR. This
complex controls EGFR/ERK1/2 activation upon cell-cell contact.
Pre-invasive lung cancer lesions are characterised by loss of contact inhibition, increased
epithelial proliferation and elevated EGFR activation and my findings identify loss of
LRIG1 as an early event in the pathogenesis of squamous cell lung carcinomas and
provide insight into elevated EGFR activation.
As loss of LRIG1 has been identified as one of four key events that predict patient
outcome across 5 tumour types including 129 lung squamous cell carcinoma patientsChapter 5. Discussion
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(Rouam, Moreau et al. 2010) I propose that this as a general mechanism for controlling
homeostasis in other epithelial tissues. This has widespread implications for the role of
cell-cell contact inhibition and regulation of EGFR signalling in development, tissue
homeostasis and disease.
EGFR and E-cadherin are known to co-localise on cell-cell contact as I have also
demonstrated. Others have shown that while E-cadherin protein levels increase five times
at cell confluence, EGFR mRNA and protein levels remain constant but tyrosine kinase
activity is reduced (Takahashi and Suzuki 1996). The mechanism by which EGFR
activation is reduced at cell confluence was not previously understood. A postulated way
of producing this fall in EGFR phosphorylation is a direct inhibitory interaction between
E-cadherin and EGFR but there is no data to my knowledge to support this. My data
however shows that the endogenous EGFR inhibitory molecule LRIG1 is also recruited to
the complex at cell confluency and is required for density dependent growth inhibition.
LRIG1 is expressed in all tissues (Nilsson, Vallbo et al. 2001) and endogenous and
synthetic LRIG1 has been confirmed to be plasma membrane bound by cell surface
biotinylation/precipitation and confocal immunofluorescence and laser microscopy
(Nilsson, Starefeldt et al. 2003). Previous data suggest LRIG1 blocks EGFR activation
through two possible mechanisms. First, LRIG1 transcript and protein are known to be
upregulated after EGF stimulation which is thought to be a negative feedback mechanism
whereby it associates with all four EGFR analogues and both proteins are subsequently
ubiquitinated by ubiquitin ligases (Gur, Rubin et al. 2004). Alternatively LRIG1 has been
postulated to bind EGFR in a monomeric ‘attenuated’ state. This is because LRIG1 with
the intracellular domain, including c-Cbl E3 ubiquitin ligase binding domain deleted, still
attenuates EGFR activity without physical down regulation of the protein and withoutChapter 5. Discussion
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competing for EGF binding (Goldoni, Iozzo et al. 2007). My data suggest the latter maybe
the case in density dependent growth inhibition as I see no down regulation of the EGFR
protein itself but a dramatic fall in EGFR activity at cell-cell contact with LRIG1
expression.
I have therefore established LRIG1 as an important tumour suppressor gene in lung
cancer with its loss occurring in the pre-invasive stages of cancer development. LRIG1
loss appears to be among the earliest abnormalities occurring in pre-cancerous airway
epithelium possibly leading to abnormal areas of proliferative epithelium that attract
subsequent genetic mutations. Examination of data from expression profiling of CIS
lesions confirms LRIG1 loss in CIS with a six fold fall compared to normal epithelium
(Lonergan, Chari et al. 2010). Understanding the mechanism of LRIG1 loss in the airways
of smokers and whether this phenotype can be reversed may have important impacts on
future chemopreventative strategies.
For future work I would like to examine the mechanism of LRIG1 downregulation in
human tissues. First I would examine for LOH at its chromosomal location of 3p14 and
second I would like to look at the methylation profile of the gene and its promotor.
The Wnt Pathway
In chapter 4, I examine the canonical Wnt pathway. I find that -catenin regulates tracheal
epithelial stem cell growth and lineage choice through modulation of E-cadherin and
intercellular adhesiveness. I demonstrate that -catenin becomes activated within basal
stem cells subsequent to tracheal damage and that inhibition of -catenin signallingChapter 5. Discussion
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decreases cell proliferation and inhibits normal epithelial repair. Separately, K14
positive basal cell-specific -catenin activation restricts ciliated cell differentiation,
promotes increased proliferation, and reduces cell adhesiveness both in vitro and in vivo.
In humans with basal cell-derived pre-invasive squamous lung cancer lesions there are
positive correlations between elevated -catenin signalling, disease severity, epithelial
proliferation, and an EMT phenotype. All of these effects are recapitulated following
direct inhibition of E-cadherin, supporting a mechanism in which stem cell -catenin
signalling directs airway epithelial growth and lineage choice via modulation of
intercellular adhesions.
My discovery of a role for -catenin in upper airway repair is consistent with earlier
works investigating the role of -catenin in distal lung development, homeostasis and
repair. In particular, genetically modified mouse models in which -catenin is activated
throughout developing airways exhibit reduced ciliated cell differentiation, expansion of
bronchio-alveolar duct junction stem cells (BASCs), and increased epithelial proliferation
(Okubo and Hogan 2004; Mucenski, Nation et al. 2005; Reynolds, Zemke et al. 2008;
Zhang, Goss et al. 2008; Li, Li et al. 2009; Voronina, Takemaru et al. 2009). Some of
these models also exhibit tumour development and hyperplasic epithelial polyp formation
that are reminiscent of human lung cancers (Mucenski, Nation et al. 2005; Li, Li et al.
2009). However, my studies are the first to demonstrate a direct relationship between
stem cell -catenin signalling, intercellular adhesions, epithelial growth and lineage
choice in human preinvasive lung cancers.
In addition to the aforementioned similarities there are several distinctions between my
results and those of earlier studies. These differences include my observation thatChapter 5. Discussion
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-catenin signalling within tracheal stem cells is by itself sufficient to promote epithelial
proliferation, enhanced basal and secretory cell differentiation, and hyperplasia. I also
found that -catenin signalling within tracheal stem cells was necessary for normal
epithelial repair. I feel these differences are best explained by the choice of transgenic
mouse model. Importantly, the present work represents an investigation of the role of
-catenin signalling specifically within K14-expressing stem cells of adult mice upon
exposure to exogenously administered tamoxifen. These mouse models therefore avoid
any potentially confounding developmental, compensatory, and / or off-target transgene
effects that are a component of earlier studies (Okubo and Hogan 2004; Mucenski, Nation
et al. 2005; Reynolds, Zemke et al. 2008; Li, Li et al. 2009).
A key finding was my observation in work done with Dr Adam Giangreco that -catenin
directly modulates cellular EMT phenotypes including E-cadherin abundance and
transcription of Twist, Snail, Slug, and Cyclin D1. I found that E-cadherin inhibition and
subsequent loss of adherens junctions, functions as a molecular switch to regulate tracheal
epithelial cell growth and differentiation.These results are consistent with identified roles
for both -catenin and E-cadherin in directing epithelial stem cell phenotypes in other
tissues (Heuberger and Birchmeier 2010). Notably, skin development and tumour
initiation are both known to be regulated by basal stem cell -catenin signalling
influencing intercellular adhesions (Jamora and Fuchs 2002; Jamora, DasGupta et al.
2003).
Although associations between pre-invasive cancer severity and cellular
epithelial-to-mesenchymal transition (EMT) phenotypes already exist, the mechanisms
responsible for regulating EMT phenotypes during lung tumour initiation and progressionChapter 5. Discussion
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have largely remained elusive (Foster, Banerjee et al. 2005). It is now appreciated that
dysregulated -catenin signalling is of central importance in driving an EMT phenotype
associated with epithelial diseases (Heuberger and Birchmeier 2010). My data provides
the first evidence that increased -catenin signalling directly influences lung EMT
phenotypes via modulation of cellular adhesions. My results also provide a simple
mechanism to explain the recent observation that several -catenin signalling pathway
components are associated with poor human lung cancer outcomes (Nguyen, Chiang et al.
2009).
My demonstration of functional links between -catenin signalling, E-cadherin inhibition
via Twist, Slug and Snail, and airway stem cell growth and differentiation may explain
how -catenin signalling pathway components can become overexpressed in squamous
cell carcinomas despite a paucity of identified -catenin mutations associated with this
disease (Konigshoff and Eickelberg 2010). My study identifies novel roles for -catenin
in normal and disease-associated tracheal stem cell growth and lineage choice advances
our understanding both of fundamental airway stem cell biology as well as identifies an
important regulatory mechanism for human lung cancer differentiation.
Future work could pursue the known regulators of EMT that are activated in my murine
models. I have demonstrated that the canonical -catenin pathway is important but there
are currently no therapeutic options involving this pathway due to its global influence in
tissue homeostasis. If a particular downstream pathway (Snail, Slug, Twist) is responsible
for the majority of the phenotype demonstrated I could pursue this in cancer models and
determine its role in the early stages of lung cancer development, again possibly
discovering a new therapeutic for this miserable disease.Chapter 6. References
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